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         Introduction 
  
INTRODUCTION 
 
Siddha system of medicine is the oldest among the Indian systems of medicine 
founded by siddhars and is also known as Tamil maruthuvam . 
 
The origin of the siddha system dates back to BC 10,000- BC 4000, according 
to Thiru T.V Sambasivam pillai siddha medical dictionary.  
 
The word ‘siddha’ comes from the word ‘siddham’ Siddha means ‘knowledge 
or wisdom’ 
 
Siddham means an object to be attained on perfection or ‘heavenly wisdom’ 
One who had attained perfection in life is called ‘siddhar’. 
 
Siddhars  were indeed true scientists who discovered and displayed god to the 
common people through their divine wisdom, medicines and elixirs with which they 
treated the incurable diseases of mankind. 
 
Siddhars prepared varieties of medicines such as Parpam, Chenduram, 
Pathangam,Kattu, Kalangu, Chunnam, Satthu, Guru kuligai etc..From 
herbs,metals,minerals and animal products. 
 
Siddha system is holistic system of medicine which treats individual both 
spiritually and physically. The treatment varies for different individuals based on their 
physical constitutions (Prakriti) 
 
Siddha system of medicine classifies disease into 4448 types .According to 
this system of medicine , the human body is made up on three humours – vali, Azhal, 
Iyyam .In  normal healthy condition ratio between them being 1:1/2:1/4. 
 
                           
                       
                           
                             ” 
-         
   
When the normal ratio of these humours – Vali, Azhal, Iyyam is disturbed, disease will occur. 
                            
                 .                     -        
     
                         
                          
 
                
                                    -          
   - 
The factors which affect this equilibrium are environment, climatic 
conditions, diet and abnormal physical activities etc. 
 
As per yoogi vaithiya sinthamani vatha disease is classified as 80 
types. One such type is keelvayu otherwise called as Santhuvatham.  As per sabapathy 
kaiyedu keelvayu is further classified into 10 types. One such type is Azhal keel vayu. 
As per sabapathy kaiyedu  Azhal keel vayu is a disease with the symptoms of pain 
and swelling in the knee joints, fever difficulty in walking etc…it has the correlation 
with Osteoarthritis(OA) of modern science. 
 
There are many diseases commonly affecting the middle aged and 
elderly people. One among them is Osteo arthritis which is given importance as it is 
mainly interfering with the principal function of human beings (i.e) locomotion. 
 
   The prevalence of OA in India is very high. The distribution of OA in 
men  and women is similar. The prevalence of osteoarthritis between the age of 40-65 
is 68% Approximately 4 out of 100 people are   affected .  Before age 45  more men 
have it, while after age 45 it is more common in women.60% of women are  affected. 
Menopausal women are particularly prone to it. 
 
Hence the author is interested to try effective remedy to this patients as 
said in Siddha literatures which the application of basic principles of Siddha and also 
supporting by modern parameters 
 The medicine chosen to this disease are Sarva noi  Linga Chenduram (Internal) 
(Ref- Anuboga Vaithiya Navaneetham , Part 4,Hackim PA. Mohammed Abdullah 
Sayubu  , Edition:  pg no 52 &53 and Maasha thylum (External) (Ref- Vaithiya 
Sinthamani ( Sigicha Rathina deepam  Pg no:2C.Kannusamipillai  Edition 2007 
    
As per siddha text book the above said siddha formulations are found 
to possess antivatha property. They would be cost effective, efficacious and easy to 
prepare. 
    
           
          
 
            
 
Aim and         
     Objectives 
  
AIM AND OBJECTIVES 
AIM 
The principal aim of the present study is 
 To evaluate the therapeutic efficacy of the Siddha formulations sarva noi linga 
Chenduram (Internal) and Maasha thylam (External) in the treatment of Azhal 
keel vayu (Osteo arthritis). 
OBJECTIVES 
PRIMARY OBJECTIVE 
 To evaluate the therapeutic efficacy of the Siddha drugs sarva noi linga Chenduram 
(Internal) and Maasha thylum (External) in reducing the pain in Azhal keel vayu (Osteo  
arthritis). 
SECONDARY OBJECTIVE 
 To conduct a clinical trial with a well defined proforma on the patients identified 
with “Azhal keel  vayu ”. 
 To evaluate the safety of the test drugs (Acute and Sub acute toxicity studies) to be 
carried out as per WHO guidelines. 
 To study the influence of other co factors such as age, sex, dietary habits, family history, 
socio economic status, habitat etc on the disease. 
 To study Azhal keel vayu on the basis of  
            (a) Mukkutram                   (b) Udalkattugal                  (c) Envagai thervugal etc         
 To find out the side effects / adverse effects of the drug “SARVA NOI LINGA 
CHENDURAM (Internal) and MAASHA THYLUM (External)” if any. 
 To screen the biochemical constituents of the drug. 
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  Siddha  Aspects 
  
  LITERATURE REVIEW 
SIDDHA ASPECTS 
Universe originally consisted of atoms which contributed to the five 
basic elements (pancha boothas) namely Earth, water, fire, air, and ether which 
corresponds to the five sense of the human body and they were the fundamentals of 
all human body and all the corporal things.  
 
The food we eat has six tastes namely sweet, sour, salt, bitter, pungent 
and astringent. Each of them is a mixture of five basic elements 
 
     - -     +    
      -     +   
     -     +   
      -       +    
       -       +   
      -       +    
Pancha poothas are the foundations for three humours  (vaatham, 
piththam, kabam) which are the pillars that support our body structure. 
Vaayu  + Aagayam constitute vaatham 
Theyu constitute piththam  
Appu  + Mann constitute kabam 
Any alterations in the level of three humours  affects the normal functions of the 
body.  
AZHAL KEEL VAAYU 
  In Siddha literature Azhal keel vaayu described under vatha diseases. 
Keel vaayu is the general term that includes all kinds of joint disorders. 
Description of the nomenclature 
Azhal keel vaayu        =   Azhal + Keel + Vaayu 
Azhal              =   Pitham 
Keel                 =   Joint 
Vaayu             =   Vatham 
Initially the joint is affected by the vitiated vatham. Pitham and kabam 
accompany later. It is a disease which is common in pitha kaalam (middle 1/3 of the 
lifespan). 
TYPES OF KEEL VAAYU 
 
Azal keel Vaayu is one among the ten types of Keel vaayu, which is mentioned 
in the text Siddha Maruthuvam, the ten types of Keel vaayu are: 
1. Vali keel vaayu 
2. Azhal keel vaayu 
3. Iyya keel vaayu 
4. Vali  Azhal keel vaayu 
5. Vali  Iyya keel vaayu 
6. Azhal Vali keel vaayu 
7. Azhal Iyya keel vaayu 
8. Iyya Vali keel vaayu  
9. Iyya  Azhal keel vaayu 
10.Mukkutra keel vaayu 
AETIOLOGY  
SEASONAL FACTORS: 
‘’                           
                      
                          
                      
                      .’’            
                     
It is said that the vatha diseases are precipitated in the months from Aani to 
Karthigai (June to December), hence the seasonal factors are involved and facilitate 
the vatha diseases. 
                               
                    –       
                            
                   ”      -                    
In muthuvenil kalam the increased solar radiation increases the 
evaporation of water content from the body in turn increases the kabam and vatham 
thathus resulting in the production of vali diseases. 
 
DIET 
                               
                                 
                                   
                                  ’’ 
 
-             
Vatha disease is caused due to the following reasons:  
 
  
 Excessive intake of tubers  
 Excessive intake of chill foods 
 Wandering in chill air 
 Getting drenched in rain 
 Living in hilly region 
 Excessive sexual  desire  and 
 Heredity 
‘’                                         
                                  
                                 
                                 ‘’ 
-            
  Excessive intake of bitter,pungent, astringent  and  acrid taste food, 
intake of varagu, thinai and altered sleep pattern also contribute to vatha disease.  
In Agathiyar kanma kaandam.., 
               
                        
                            
                      
                      
                      
                               
                        
                              
 
-           
 According to Agathiyar kanma kaandam, cutting young trees and fracturing 
the legs of animals will produce Vatha diseases. 
 
VATHA DISEASES 
                              
                              
                           
                 
-                    
As per Theraiyar, Vatham is being hailed as the king, who rules the fort 
(Body) and enables the dwelling of the citizen (Uyir) in the fort. Hence Theraiyar 
lauds Vatham as the prime force in normal state. 
HABITS: 
                                     
                                    
                                 
                                   ’’ 
-              
  The factors like, walking under hot sun, increased sexual desire, and 
excessive in take of  water and bitter guard etc, also disturbs the normal functions of 
Vaatham. 
 
                           
                           
                       
                      
                       
                          
                            
                          ” 
-                  
  Excessive intake of bitter, astringent, pungent taste, excessive intake of 
food, intake of rain water, altered sleep rhythm, increased starvation and increased 
sexual desire will produce vatha diseases. 
CHARACTERS OF VATHA DISEASES: 
 
                               
                                 
                               
                                 ’’ 
 
-                      
  When vatham increases gsses increases, many diseases may arise like 
sanni, body loses the weight. 
 
                                   
                                       
                                      
                                         ‘’ 
- (            ) 
When the Vatha kutram aggravates it will produce the following signs and symptoms:  
 
 loss of appetite, 
 Excruciating pain 
 Fever 
 Cough, 
 Insomnia 
 Shivering of the body 
 Nervous weakness 
 Joint pain 
 
 “                                   
                                 
                                     
                                  ” 
-                   
 
  According to Agathiyar vaithiya Kaaviyam, the deranged vali 
produces pain in the joints of the hands and legs, flatulence, constipation, scanty 
micturition, fever with rigor, generalized body pain and increased sweating. 
 
“                                   
                                  
                                  
                                  ” 
       -              
  According to Theraiyar vagadam, the deranged vali produces pain in 
the joints, head ache, constipation, increase salivation, fever with rigor and loss of 
normal complexion. 
“                       
                            
                           
                ” 
-            
  According to Theraiyar karisal, the deranged vali produces blackish 
discolouration of body, feverishness, increased sweating, indigestion and dyspnoea. 
                                  
                                    
                             
                            .” 
 
                                   
                                  
                               
                                . 
                      1000 
  According to Agathiyar vatha Kaaviyam 1000, the deranged vali 
produces abdominal discomfort, pain in joints, oliguria, dysuria, constipation and 
flatulence. 
SITES OF VALI 
            - The sites of vali 
 “                           
                              
                           
                                 ! 
 
                              
                             
                            
                             !” 
-            
  According to vaithiya sathagm, vatham dwells in the following 
places: Umbilicus, rectum, faecal matters, abdomen, anus, bones, hipjoints, skin, 
navel plexus,Joints, Hair follicles and muscles. 
 “                   ” 
-       
                            
                     . 
-         
  According to sage Thirumoolar and sage Yugi, the places of vatham 
are the anus and below the navel region. 
                      
                          
-                         
  According to Anupoga vaithiya bramma ragasiyam,  vatham exists 
between the umbilicus and navel region. 
Properties of Vali:      
                              
                             
                           
                       
-                    
Natural properties of Vatham: [Ref: Noi Nadal part-1] 
 
1. Giving briskness 
2. Expiration and Inspiration 
3. Functioning of the mind, thoughts and body 
4. Regulation of the “Fourteen Physiological Reflexes”(Vegam). 
5. Functioning of the “Seven Udal Kattukal” uniformly 
6. Protection and strengthening of the five sensory organs. (Iymporigal) 
  
Symptoms of Vatham thodam: 
1. Body ache 
2. Pricking pain 
3. Tearing pain 
4. Nerve weakness 
5. Mental distress 
6. Movements 
7. Joints pain 
8. Traumatic pain 
9. Dislocation of joints 
10. Weakness of organs 
11. Paralysis of limbs 
12. Polydypsia 
13. Severe pain in calf and thigh muscles 
14. Bony pricking pain 
15. Anuria and constipation 
16. Unable to do flexion and extension of the limbs 
17. All tastes to be like astringent 
18. Excess Salivation 
             
      - Rough 
       - Dry 
       - Light 
        - Cold 
       - Unstable 
        - Subtl 
 
                     
      - Soft 
       - Unctuous 
      - Heavy 
       -  Hot 
      - Stabl 
       - Solid 
                 
                 
                       
                         
            
                 
     ,     ,                          
             
        ,                        
             
In Azhal keel vayu  
  NAME    
   LOCATION PHYSIOLOGICAL FUNCTIONS 
Abanan 
Lower abdomen 
and Extremities 
Responsible for urination, defecation and 
parturition, Menstruation, ejaculation of the 
sperm. 
Viyanan 
Heart  Responsible for movements of all parts of the 
body and sensation. 
Samanan 
Stomach Responsible for proper   digestion      
 
 Abanan is affected and so constipation is produced. 
 Viyanan is affected it renders difficulty in movements of the knee joints. 
 Samanan is also affected because disturbed state of other vaayus 
 
                       : 
 
                  
                
                  
                 
                
                  
                  
               ” -              
 
It is characterized by swelling of joints associated with severe pain and 
pyrexia. Since it is not quickly responding to medicine the prolonged medical care is 
said to be essential. As pitha increases kaba (mucous) in the joint decrease and hence 
dryness occur. So, during flexion of the joint crepitation is produced. 
         - Diagnosis in Siddha: 
Piniyari muraigal (Method of Diagnosis) is based upon three main principles, 
1) Poriyal Arithal(Inspection) 
2) Pulanal Arithal (Palpation) 
3) Vinaathal(interrogation) 
1. Poriyal Arithal (Inspection): 
   “Poriyal arithal” means examining the “Pori” of the patient by the 
“Pori” of the physician for proper diagnosis. Pori is considered as the “Five sense 
organs” of perception namely, 
1) Mei  (Skin)  
2) Vai  (Tongue) 
3) Kan  (Eye) 
4) Mookku   (Nose) 
5) Sevi   (Ear) 
2. Pulanal arithal (Palpation): 
              Pulan are five object of senses. They are, 
1) Smell 
2) Taste 
3) Vision 
4) Sensation of touch 
5) Hearing 
            “Pulanal arithal” means examining the “Pulan” of the patient by the “Pulan” of 
the Physician to diagnose a disease. 
3.Vinaathal (Interrogation): 
            Vinaathal is gathering information regarding the history of disease, its 
clinical features etc., from the patient or his/her close relatives useful when the patient 
is not in a position to speak or in the case of a child. 
 
ENN VAGAI THERVUGAL (Eight diagnostic Tools): 
            It is a unique method of diagnosis in Siddha system of medicine. They 
are clearly explained by Siddhar Theraiyar 
 
                                     ” 
-        
     
                             
                      ” 
 
-                            ,     1 
Hence the diagnosis is made by the following 
1. Naadi (pulse) 
2. Sparisam (sensation to touch) 
3. Naa (tongue) 
4. Niram (colour) 
5. Mozhi ( voice) 
6. Vizhi (eyes) 
7. Malam ( faeces) 
8. Moothiram (urine) 
Azhal keel vayu in relation with Envagaithervugal, 
NAADI : 
                                              
                   . 
                             , 
                      , 
                             
                         
                        
                          
                           
                         ” 
-                      
 
 Naadi is responsible for existence of life and can be felt one inch away 
from the wrist joint  on radial  side by means of palpation with the tips of index, 
middle and ring fingers corresponding to  vaatham, pitham, kabam respectively. 
 
  The three humors vaatham, piththam and kabam exisits in the ratio  
1:½ :¼  normally. Derangement in these ratios leads to various disease entities. 
 
   The three “ uyir thathukkal’’ are formed by the combination of three 
nadigal with three vaayu. 
 
a) Edakalai   + Abaanan  =  Vaatham 
b) Pinkalai   + Piranan  = Piththam 
c) Suzhumunai  + Samanan  = Kabam 
 
“                                    
                                  ” 
-            
When piththa gets vitiation it accompany with vatha and causes pain in every joints. 
“                               
                                       
-            
When kapha and vatha are vitiated pain occurs in the nerves and lower extremities. 
 “                                     ’’ 
-          
When vatha gets vitiation pain occurs in the joints and lower extremities. 
 “                                  ’’ 
-            
When kapha vitiated with vatha, it causes pain and swelling in the joints. 
 “                                 
                                    ’’ 
-          
When piththa vitiated with kapha it results in stabbing pain in bones and joints. 
In Azhal Keel Vayu the following types of naadi can be seen commonly. 
They are, 
   a ) vaatha piththam 
   b ) vaatha kabam 
   c ) piththa vaatham  
   d ) piththa kabam 
   e ) kaba vaatham 
2. Sparism (Sensation to touch): 
In Azhal keel vaayu mild warmth noticed over the affected joint. 
3. Naa (Tongue): 
In Azhal keel vaayu no abnormality is seen in Naa. 
4. Niram(Colour): 
  In Azhal keel vaayu no abnormality is seen in Niram. 
5. Mozhi: 
It constitutes high, low-pitched voice, nasal speech, hoarseness of voice 
slurring and incoherent speech etc. 
In Azhal keel vayu no abnormatlities are seen normally. 
6. Vizhi: 
Both motor and sensory disturbance of eye are noticed. Redness of eyes, 
paleness, excessive lacrimation, swelling, corneal ulcers, sunken eyes may be noted 
for. 
In Azhal keel vayu  no abnormatlities are seen normally. In anaemic patients 
pale conjunctiva may be noted. 
7. Malam: 
Vatha type: Black coloured stools with constipation. 
Pitha type: Loose stools with yellowish red colour 
Kabha type: White coloured stools with mucous 
Thontha type: Stools possess some of the features of two thodams 
In Azhal keel vayu  constipation was reported in some of the cases. 
VIII. Moothiram: 
Neerkuri and Neikuri (Oil on urine sign) are special diagnostic methods 
regarding urine (Moothiram). 
 
Neerkuri and Neikkuri: 
 
                         
                           
                      
                       
                        
                         ’’ 
-                   
 
Prior to the day of urine examination the patient is instructed to take a 
balanced diet and quantities of food must be proportionate to his routine intake. The 
patient could have no disturbed sleep. After waking up in the morning, the first urine 
voided is collected in a clear wide mouthed glass bowel and is subjected to analysis of 
“Neerkkuri and Neikkuri” within one and a half an hour. 
                             
                       ‘’ 
                   
Voided urine has the following characters 
1. Niram   - Colour 
2. Edai   - Specific Gravity 
3. Manam   - Smell 
4. Nurai   - Frothy nature 
5. Enjal   - Deposits 
Apart from these , the frequency of urination , abnormal constituents , such as sugar, 
protein, presence of blood, pus, also to be found out. 
 In Azhal keel vayu patient straw  coloured urine was  noticed. 
Neikuri: 
   The speciality of Neikuri is stated in the following verse. 
 “                           
                           
                           
                         
                            
                             
-                                 1  
 The process of dropped gingely oil indication 
“                       
                            
                         
                       
                      ’’  
      -                                  1 
   The collected specimen was examined by the following method. The 
collected urine specimen is kept in a glass bowel and observed under direct sunlight 
without shaking the vessel. Then drip one drop of gingely oil and observe the 
spreading pattern and concludes as follows,  
                     
                      
                           
                    
                    
                        ’’ 
-                                             1 
When the oil drops lengthens like a snake it indicates ‘vatha Neer’ 
When the oil drops spreads like a ring it indicates ‘pitha Neer’ 
When the oil drops remains that of pearl it indicates’ kaba Neer’  
 
PARUVAKAALAM (Seasonal variations): 
            
S.No STATE OF KUTTRAM KAALAM 
1. Vatham  thannilai  
adaithal                 
Munpani kaalam, Pinpani 
kaalam,Koothir kaalam, Elavenil 
kaalam                                                                    
 
2. Vatham thannilai valarchi Muthuvenil kaalam 
 
3. Vatham vetrunilai 
valarchi 
Kaarkaalam 
 
 
Vatham vitiates during Muthuvenil, i.e during summer, the 
environment is hot it leads to dryness of the body and the body loses its energy 
through perspiration and may impair the digestion.  
  So, in Azhal keel vayu the disease shows its exacerbation during 
muthuvenil kaalam.  
 
THINAI (Geographical Distribution): 
 
It is divided into five types. They are, 
         
S. NO THINAI LAND 
AFFECTED 
HUMORS 
1. Kurinchi 
Mountain and its surroundings 
Hilly terrain 
Kabam 
2. Mullai 
Forest and its surroundings 
Forest ranges 
Pitham 
3. Marutham 
Farm land and its surroundings 
Cultivable lands 
All three humors 
are in equilibrium 
4. Neithal 
Sea shore and its adjoining areas 
Coastal belt 
Vatham 
5. Palai 
Desert and its surroundings 
Arid zone 
All three humors 
are affected. 
 
                           
                    –        
                           
                    . 
-                   
Geographical distribution plays a vital role in altering Mukkutrams. 
According to Siddha, vatha diseases are predominant in Mullai and Neithal Thinai. 
  
UDAL KATTUGAL: 
Our body consists of seven udal kattukal.  
  
SL. 
No 
UDAL 
KATTUGAL 
FUNCTIONS 
1. Saaram   It gives strength to the body and mind. 
2. Senneer                            Saaram after absorption is converted into senneer. It is 
responsible for knowledge strength, boldness and healthy 
complexion. 
3.  Oon                                   Gives structure and shape to the body and is responsible for 
the movements of the body. 
4.  Kozhuppu Lubricates the organs on its own works. 
5.  Enbu Protects the vital organs and used for movements and 
nominates the body structure. 
6.  Moolai Present inside the bones and it gives strength and maintains 
the normal Condition of the bone. 
7.  Sukkilam(or)  
suronitham                                    
Responsible for the reproductive function of species. 
 
S.no 
UDAL 
KATTUKAL 
INCREASED CONDITIONS DECRESED CONDITIONS 
1 Saaram                      Loss of appetite, excessive 
salivation,diminished activity, 
heaviness, pallor, cold, decreased 
physical constituents, dyspnoea, 
flatulence, cough, excessive 
sleep.            
Tiredness,dryness of skin, 
Laziness, loss of weight, 
lassitude, and irritability while 
hearing heavy noise. 
2 Senneer Boils and tumours in different                                
Parts of the body, 
Spleenomegaly, 
pricking pain, increased blood   
Pressure, reddish eye and skin, 
jaundice, leprosy, haematuria etc.                           
Affinity to sour and cold food, 
nervous  debility, dryness , 
pallor.  
3 Oon Tubercular adenitis, Tumours or 
extra growth around  the neck,  
cheeks, abdomen, thigh, 
genitalia. 
Lethargic sense organs, pain in 
the joints, muscle wasting in 
mandibular region, gluteal 
region, penis, thighs. 
4 Kozhuppu                      Identical feature of increased 
flesh, tiredness, dyspnoea on 
exertion, extra musculature in 
gluteal region, external genetalia, 
chest, abdomen thighs  
 Loins Pain, spleenomegaly, 
emaciation. 
5  Enbu                                Excessive ossification and 
dentition 
Joint pain, falling of teeth, 
falling and splitting of hairs and 
nails.                                          
6  Moolai                        Heaviness of the body and  eyes, 
swollen inter phalangeal joints, 
oliguria  and non healing ulcers. 
Osteoporosis, Blurred vision. 
  
7 
 
Sukkilam or                     
Suronitham                 
 Increased sexual activity and                              
 signs identical to urinary calculi                              
Dribbling of sukkilam/ 
suronitham or senneer during 
coitus, pricking pain in the 
testis, inflammed and contused 
external genitalia. 
 
  
In Azhal keel vaayu,  
 Saaram, Kozhuppu, Moolai and Enbu thathukkal are commonly affected. 
Saaram   : Weakness, pain in knee joints 
  Kozhuppu  : Morning stiffness occurs in affected knee joints 
 
  Enbu   : Pain occurring in affected knee joints, crepitations present 
 
  Moolai  : Osteoarthritis in knee joints 
 
UYIR THATHUKKAL: 
             Human body is influenced by three uyir thathukkal i.e, Vatham, Pitham and 
kabam. They are responsible for normal physiological conditions of the body. 
Vatham 
DESCRIPTION OF VATHAM: 
The Siddha classical texts divide the general principles of Vatham into ten 
subsidiary forms that differ from one another by their localizion in the body 
(Anatomical) and by their particular functions (Physioloical). They are 
1. PRAANAN: (Heart Centre) 
It refers to be in the chest. It maintains the action of the heart, the functioning 
of the mental faculties of perception and concentrations and also cares for the arteries, 
veins and nerves. It regulates the respiration and digestion. It is otherwise called as 
“Uyirkkaal”. 
2. ABAANAN: (Moolaadharam Centre) 
It corresponds to the pelvic area and controls the excretion. It is focussed in 
the lower part of the gut and also occupies the sites in the bladder and genitals. It has 
a tendency to travel downwards. It moves in the whole Genito Urinary Tract and 
regulates the defaecation, micturition, menstruation, parturition and ejaculation. It is 
otherwise termed as “Keezhnokkumkaal”. 
3. VIYAANAN: (Fore head Centre) 
 It corresponds to the naso cilary area i.e  at the root of the nose and base of 
the skull and controls the will. It helps in the circulation of energy throughout the 
entire nervous system and the movements of various parts of the body. It also 
transports nutrients and blood throughout the entire body. It is also known as 
“Paravukaal.” 
 4. UDHAANAN: (Throat Centre) 
 This corresponds to the pharyngeal area in the throat region and controls 
speech and breathing. It is also responsible for the physiological reflex actions like 
vomiting, hiccup, cough, etc. It has the tendency to travel upwards. It is otherwise 
named as “Melnokkukaal.” 
 
5. SAMAANAN: (Navel Centre) 
 It corresponds to in the navel region and controls digestion. It selects the 
useful substances from the swallowed food and supplies them to the whole body. It 
balances the other ‘Vayus” it is also called “Nadukkaal.” 
 
6. NAAGAN: 
 It is responsible for the intelligence of an individual, winking, singing and pilo 
erection. 
 
7. KOORMAN: 
 It is responsible for yawning, closing of mouth (movement of lower jaw) 
winking, shedding of tears, vision and opening of the eyes. 
 
8. KIRUGARAN: 
 It is responsible for salivation and nasal secretion. It helps in digestion and 
meditation. It produces cough and sneeze. 
9. DHEVATHATHAN: 
 It is responsible for laziness, lassitude, quarreling, arguing, and also for much 
anger. It helps movements of the eyeball in various directions and is present in genital 
and anal region. 
 
10. DHANANJEYAN: 
 It is present in nose and responsible for swelling of the body and tinnitus. It 
leaves the body by blowing up the cranium only on the third day after death. 
 
[Ref: Siddha Maruthuvanga Churukkam] 
Piththam 
Piththam is responsible for all the transformation. piththam is located 
in urinary bladder,heart, umbilicus,abdomen,blood, sweat, skin and eyes. 
Piththam is classified into 5 types. 
1.Anala piththam  - Responsible for digestion of food 
2.Ranjaga piththam   - Responsible for colour of blood 
3.Sathagam - Located in heart and is responsible for 
   normal activities of the body. 
4.Alosagam   - Responsible for normal vision  
5.Prasagam    - Responsible for the complexion of skin 
In  Azhal keel vayu  
Sathagam affected- Difficulty in walking, climbing upstairs, squatting, 
sitting cross legged (Daily activities). 
Kabam  
Stabilizes, maintain and lubricates the joints and helps in their movements. 
Kabam is found in samanan, semen, brain, head, tongue, nose, bones, bone 
marrow, fat, nerves, chest, blood, large intestine, eyes, stomach and pancreas. 
Kabam is clasiified in to 5 types they are  
1. Avalambagam-  Heart is the centre for avalambagam. It controls all other      
                                    Forms of kabam. 
2.Kiletham-   Stomach is the center for kiletham. It give moisture and   
                                    Softness to the ingested food and helps  digestion. 
3. Pothagam-   Tongue is the center for Pothagam and it is responsible  for    
                                    the sense of taste 
4. Dharpagam -  Head is the center for Dharpagam. It gives cooling effect to  
                                    eyes 
5. Santhigam-   It lies in the joints and it is responsible for the  locomotive  
                                    action of movable bony joints. 
  
In Azhal keel vayu , 
 
 Santhigam affected - Produce difficulty in movements of the knee joints. 
 
 
 
  
S.No HUMOUR               INCREASE             DECREASE 
1 Vatham Distended abdomen, 
Constipation, weakness, 
Insomnia,tremors, guiddiness, 
Blackish discoloration of 
body 
Body pain, feeble voice,  
syncope,diminished 
capability of brain, 
symptoms associated with 
growth of kabam. 
2. Piththam Yellowish discoloration of 
eyes,Skin, urine and motion, 
Polyphagia, polydypsia, 
Burning sensation all over 
the body, sleeplessness. 
Cold, Pallor, 
Decreased appetite. 
3. Kabam  Loss of appetite, excessive 
salivation, heaviness of body, 
Dyspnoea, excessive 
sleeping, 
Diminished activity. 
Prominence of bone edges, 
Profuse, palpitation, 
sweating, Guiddiness, 
dryness of joints. 
VARIATION OF MUKKUTRAMS 
Vatham is mainly responsible for proper loco-motor functions. Bones 
and joints are considered to be the main location of vatha.  
              In Azhal keel vaayu the vatha kutram is mainly affected followed by 
pitham and Kabam. This produces the following signs and symptoms, 
 
1. Deranged viyanan leads to pain and difficulty in movements. 
2. Deranged Abanan leads to constipation. 
3. Inflammatory changes of the joints, redness and warmth are developed due to 
deranged pitham. 
4. Sathaga pitham gets affected hindering the loco motor functions. 
5. Along with vatham, kabam is also deranged, i.e Santhikam is affected and this 
leads to abnormality in joint movements. 
6. Erosions of bone margin, increased secretion of synovial fluid are developed due 
to deranged kabam. 
IMPORIGAL:  
Gnanenthiriyam are Mei, Vaai, Kan, Mooku and Sevi. 
          In Azhal keel vaayu no abnormalities are seen in Gnanenthiriyam 
KANMENTHIRIYAM:  
Kanmenthiriyam are Kai, Kaal, Vaai, Eruvaai, Karuvaai. 
           In Azhal keel vaayu “kaal” is affected and become of pain and swelling, 
morning stiffness and deformities. 
KAALAM 
 Ancient Tamilians divided a year into six different seasons known as 
Perumpozhudhu and likewise the day into six segments which are known as 
Sirupozhudhu. 
Perumpozhudhu: 
  A year is divided into six seasons. They are as follows 
 
Sl.NO. Season Months Kuttram 
1. Kaarkaalam 
Aavani & Purattasi 
August 16 – October 15 
Vatham ↑↑ 
Pitham ↑ 
2. Koodhir kaalam 
Ayppasi and kaarthigai 
October 16 – December 15 
Vatham (-) 
Pitham ↑ 
3. Munpani kaalam 
Margali and Thai 
December 16 – February 15 
Pitham (-) 
4. Pinpani kaalam 
Maasi and panguni 
February 16 – April 15 
Kabam ↑ 
5. Elavenir kaalam 
Chithirai and Vaigasi 
April 16 – June 15 
Kabam ↑ ↑ 
 
6. 
Mudhuvenir 
kaalam 
Aani and Aadi 
June 16 – August 15 
Vatham ↑ 
Kabam (-) 
 
↑  - Thannilai valarchi   (-) - Thannilai adaidhal 
 
↑↑  - Vetrunilai valarchi 
 
 In Kaarkalam Vatha diseases may occur greatly. 
 In Muthuvenil kaalam it may worsen badly. 
 
  
NOI KANIPPU VIVATHAM (DIFFERENTIAL DIAGNOSIS): 
Azhal keel vaayu is differentiated from the followings diseases, 
 
 VALI KEEL VAAYU: 
                 
                       
                 
                    
                
                     
                 
                 . 
-            
  It is characterized by excruciating pain and swelling involving  knee 
joints, hip joints, elbow joints, shoulder joints and associated with systemic 
disturbances like dryness of mouth, pyrexia, headache, palpitation, constipation and 
sweating. In advanced cases it may affect the heart and produce “Thamaraga vaayu”. 
 IYA KEEL VAAYU: 
                
                
                   
                  
               
                     
                  
                      
      -             
It is characterized by severe pain in the joints associated with emaciation 
of the body, anorexia, insomnia, cough, hiccough, vomiting, anaemia and dropsy. The 
common sites are spinal cord, hip joints and knee joints. 
 VALI IYA KEEL VAAYU: 
                 
                 
                  
                  
                    
                 
                 
                . 
-            
It is characterized by pain in the joints associated with effusions of joint fluid 
and swelling, restricted joint movements, pyrexia, fainting, insomnia, especially in 
knee joint asymmetrically, lymphadenopathy, generalized malaise, atrophy of the 
affected limb etc.  The affected joint looks like “Fox’s Head” 
 
 VALI  AZHAL KEEL VAYU: 
                    
                      
                  
                     
                
                   
                
                    . 
-             
It is characterized Indigestion,belching, flatulence constipation and increased body 
weight. Pain and rednesss burning sensation, in wrist , ankle joint, inter phalangeal 
joints.sleeplessness and fever occurs. 
  
 VALI IYA KEELVAYU:  
                  
                   
                    
                      
                     
                  
                 . 
 
                     
                 
                 
                      
                
                    
                  
               .    -            
 
It is characterized by Swelling in the both knee joint, pain and pricking 
sensation in both knee joints, inability to flex and extended upper limb and lower 
limb. Insomnia, emasiation, lymph adenopathy in axilla, inguinal region, muscular 
atrophy in affected limbs, swelling of joint resemble fox head. 
 
   
  
 AZHAL VALI KEEL VAYU  
                   
                
               
                 
                 
                   
               
                      . ! 
 -            
It  is  characterized  by  joint  pain  and swelling, inability  to  flex  and 
extend the knee joint associated with rhinitis throat soareness, sneezing, vomiting 
body pain fever. 
 AZHAL IYA KEEL VAYU 
                 
                 
               
                   
                 
                      
                
                  .   -             
 
This type of keelvayu is associated with veneral disease, in prodormal 
stage the main symptom is sever head ache, nausea, vomiting, fatigue, body ache. 
Then it aggreviate with high body temperature pain and swelling elbow and knee 
joint, inability to flewxion and extension, later swelling of the joint appearas like fox 
head, ( it shows its severity. 
  
 IYA THEEK KEEL VAYU 
 
                
                    
                
                  
                 
                    
                  
                    .   -             
 
This type of keelvayu is Rhinitis, throat soreness, joint  pain  and 
swelling, inability  to  flex  and extend the knee joint associated with rhinitis throat 
soarness, sneezing, vomiting body pain high body temperature.. 
 
 MUKKUTRA KEEL VAAYU : 
                 
                  
                  
                 
                 
                  
                
                  !    -             
 
It is characterized by Fever , pain, and swelling, swelling increases due to 
elevated kabam, delirium. if untreated can death occur. 
  
LINE OF TREATMENT 
               In Siddha system the main aim of the treatment is to cure Udarpini 
(due to Mukkuttram) and Manapini (due to changes in Mukkunam). Treatment is not 
only for perfect healing but also for the prevention and rejuvenation. 
 It is essential to know the disease, the aetiology, the nature of the 
patient, severity of the illness, the seasons and the time of occurrence must be 
observed clearly. 
Line of treatment is as follows: 
1. Kaapu  (Prevention) 
2. Neekkam (Treatment) 
3. Niraivu   (Restoration) 
                Thiruvalluvar details the duty of the physicians, i.e. study the disease, 
study the cause, seek subsiding ways and do what is proper and effective. 
                                  
                   ” 
 
                      
               ” 
              (      ) 
1)KAPPU (Prevention): 
The prevention methods for Azhal keel vaayu are as follows: 
 Control the body weight by diet and exercise. 
 Modify the nature of work which gives stress to a particular joint.  
e.g. - Avoid prolonged standing and long distance walking. 
 Avoid intake excess sour, astringent and bitter tasted foods. 
2) NEEKKAM (Treatment in Siddha): 
The aim of Neekkam is based on 
 To bring the deranged Thodams to normal equilibrium state. 
  To treat the patient with internal medicine and external medicine. 
        First the deranged vatham has to be brought to its normal state by giving 
purgation. It is mentioned in the following verse  
                      
                  
                     ” 
-                   
1. PURGATIVE: 
 In Azhal keel vaayu vatha kutram is deranged. So a purgative medicine 
Agasthiyar kuzhambu - 130 mg with ginger juice was given in early morning in 
empty stomach on the first day of treatment. 
  2.INTERNAL MEDICINE: 
Sarva noi  linga chenduram– 130 mg twice a day given with honey after food. 
                    Ref-  Anuboga vaithiya Navaneetham, part 4, pg no 53&54 
  3. E XTERNAL MEDICINE: 
   Maasha  Thylum [ ulunthu thylum ]  
                                
Ref:  Vaithiya Sinthamani ( Sigicha Rathina deepam )   Pg no:202 
               
             C.Kannusamipillai  Edition 2007     
 
4.DIET TO BE ADVISED : 
 
 VEGETABLES  :Tender brinjal, Tender drumstick, Lablab bean. 
 LEAVES   :Sessile leaves,Black night shade, Hog weed,  
 Climbing brinjal, dog mustard leaves, Curry leaf. 
 FRUITS   :Pomagranate, apple,Dates palm,country fig, 
                                          Jambul   fruit. 
 NON VEGETARIAN :Goat, prawn fish. And Advised to take milk 
  
4. DIETARY RESTRICTIONS: 
                         
‘’                                 
                            
                                 
                              ‘’ 
                   
Mustard, sesame oil. Pumpkin, country arrack, groundnut, coconut,    
mango, jackfruit,garlic, asofoetida, tobacco, bitter – guard, sesbania leaves, excessive 
sexual desire. 
 
 
 ‘’                             ‘’ 
                                        . 
 
Astringent and sour tastes to be avoided. 
  
  
 
 
        
 
   Modern  Aspects 
  
MODERN ASPECTS 
OSTEO ARTHRITIS 
INTRODUCTION: 
               Osteoarthritis can be defined as a degenerative, non-inflammatory joint 
disease characterised by destruction of articular cartilage and formation of new bone 
at the joint surfaces and margins. However, it is a misnomer and the right term is 
Osteoarthrosis or degenerative joint disease.  
   
EPIDEMIOLOGY: 
  Osteoarthritis is by far the most common joint disorder throughout the 
world, and is one of the leading cause of disability in the elderly. Although the disease 
commonly affects the cervical and lumbar spine, most epidemiologic studies report 
that it has a predilection for weight bearing  joints in the leg and certain joints in the 
hand. 
  The prevalence of osteoarthritis in all joints correlates strikingly with 
age .One third of people aged 65 years and older have knee osteoarthritis that is 
evident by radiograph. Before the age 50, men are more likely to have osteoarthritis 
than women, but after age 50,it is common in women who are more likely to be 
affected. 
Osteoarthritis is already one of the ten most disabling diseases in developed countries. 
 Farming 1-9 years increases the risk of osteoarthritis 4 times, farming 10 or 
more years increases the risk 9 times. 
 World wise estimates are that 10% of men and 18% of women aged over 60 
years have symptomatic osteoarthritis. 
 80% of those with osteoarthritis will have limitations in movement, and 25% 
cannot perform their major daily activities of life. 
ANATOMY OF THE KNEE JOINT 
 Introduction: 
The knee joint is the largest and most complex joint of the body. The 
complexity is the result of fusion of three joints in one. It is formed by fusion of the 
lateral femorotibial, medial femorotibial and femoropatellar joints. 
Injuries to the knee joint are amongest the most common in sporting 
activities and understanding the anatomy of the joint is fundamental in understanding 
any subsequent pathology in the joint. 
Type: 
It is compound synovial joint, incorporating two condylar joints 
between the condyles of the femur and tibia, and one saddle joint between the femur 
and patella 
Articular surfaces 
The knee joint is formed by 
 The condyles of the femur 
 The condyles of the tibia and  
 The patella 
The femoral condyles articulate with the tibial condyles below and 
behind, and with the patella in front. 
Ligaments 
The knee joint is supported by a number of ligaments that are, 
 Fibrous (articular) capsule 
 Ligamentum patellae 
 Tibial collateral(medial) ligament 
 Fibular collateral ligament 
 Oblique popliteal ligament                                               
 Arcuate popliteal ligament 
 Cruciate ligaments 
 Menisci(semilunar cartilages) 
 Transverse ligament 
The stability of the knee owes greatly to the presence of its ligaments. 
Each has a particular function in helping to maintain optimal knee stability in a 
variety of different positions. 
The knee joint capsule: 
            The joint capsule is a thick ligamentous structure that surrounds the 
entire knee. Inside this capsule is a specialized membrane known as the synovial 
membrane which provides nourishment to all the surrounding structures. Other 
structures include the infrapatellar fat pad and bursa which function as cushions to 
exterior forces on the knee. The capsule itself is strengthened by the surrounding 
ligaments. 
 
Menisci (semi lunar cartilages) 
The menisci are two fibro cartilaginous discs.They are shaped like 
crescents. They deepen the articular surfaces of the condyles of the tibia and partially 
divide the joint cavity into the upper and lower compartments. 
 
Functions of menisci 
 They help to make the articular surfaces more congruent 
 The menisci serve as shock absorbers 
 They help to lubricate the joint cavity 
 Because of their nerve supply, they also have a sensory function. They 
give rise to proprioceptive impulses. 
Synovial fluid 
Synovial fluid is a thick, stringy fluid found in the cavities of synovial 
joints.With its egg like consistency(synovial comes from latin for “egg”), synovial 
fluid reduces friction between the articular cartilage and other tissues in joints to 
lubricate and cushion them during movements. 
  
Muscle groups surrounding the knee joint: 
The two main muscle groups of the knee joint are the quadriceps and 
the hamstrings. Both play a vital role, both moving and stabilizing the knee joint. 
Quadriceps muscle: 
The quadriceps muscle group is made up of four different individual 
muscles which join together forming the quadriceps tendon. This thick tendon 
connects the muscle to the patella which in turn connects to the tibia via the patellar 
tendon. Contraction of the quadriceps, pull the patella upwards and leads to knee 
extension. 
 
Hamstrings muscle: 
The Hamstrings muscle function is flexing the knee joint as well as 
providing stability on either side of the joint line. 
 
Movement 
 Flexion  
 Extension  
 Medial rotation 
 Lateral rotation 
 
Flexion and extension are the chief movements. Those take place in the upper         
compartment of the joint above the menisci. 
Rotatory movements at the knee are of a small range. Rotations take place 
around a vertical axis, and are permitted in the lower compartment of the joint, below 
the menisci. 
 
Blood supply: 
The knee joint is supplied by the anastomosis around it. The chief sources are 
 Five genicular branches of the popliteal artery 
 The descending genicular branch of the femoral artery 
 The descending branch of the lateral circumflex femoral artery 
 Two recurrent branches of the anterior tibial artery 
 The circumflex fibular branch of the posterior tibial artery 
 
Nerve supply 
 Femoral nerve 
 Sciatic nerve 
 Obturator nerve 
 
LIGAMENTS OF THE KNEE JOINT 
                       
                               
 
           
  
     LOCATION OF PAIN 
 
                                  
 
       
 
 
MUSCLES OF THE KNEE  
 
                            
  
AETIOLOGY: 
PRIMARY CAUSE OF OSTEOARTHRITIS: 
Though exact cause is not known, the following factors are suspected to play 
an important role in the causation of primary osteoarthritis  
1) Endocrine 
2) Post Traumatic 
3) Inflammatory joint disease 
4) Metabolic 
5) Congenital or developmental 
6) Genetic 
7) Neuropathic  and others 
1. ENDOCRINE: 
People with Diabetes may be prone to osteoarthritis. Other endocrine 
problems also may promote development, including Acromegaly, Hypothyroidism, 
Hyper parathyroidism and Obesity. 
2. POST TRAUMATIC:  
Traumatic causes can be further divided into macro trauma or micro 
trauma. An example of macro trauma is an injury to the joint such as bone break 
causing the bones to line up improperly (mal alignment), lose of stability or damage 
cartilage. Micro trauma may occur over time (chronically). An example of this would 
be repetitive movements or the overuse noted in several occupations. 
3. INFLAMMATORY JOINT DISEASE: 
This category would include infected joints, chronic gouty arthritis and 
rheumatoid disease. 
 4. METABOLIC: 
 Disease causing errors of metabolism may cause osteoarthritis. 
Examples include Paget’s disease and Wilson’s disease. 
5. CONGENITAL OR DEVELOPMENTAL: 
 Abnormal anatomy such as unequal length of legs may be a cause of 
osteoarthritis. 
6. GENETIC: 
A genetic defect may promote breakdown of the protective architecture 
of cartilage. Examples include collagen disturbances such as Ehlers- Danlos 
Syndrome. 
7.  NEUROPATHIC: 
Diseases such as Diabetes can cause nerve problems. It may affect the 
the Joints and  limbs.  
8. OTHERS: 
Nutritional problems may cause osteoarthritis. Other disease such as 
haemophilia and sickle cell anaemia are further examples. 
 
SECONDARY CAUSES OF OSTEO ARTHRITIS: 
        The causes for secondary osteoarthritis of the knee are as follows: 
 Obesity 
 Valgus and varus deformities of the knee. 
 Intra – articular fractures of the knee, etc. 
 Rheumatoid arthritis, infection, trauma, TB, etc. 
 Hyper parathyroidism. 
 Haemophilia. 
 Syringomyelia  
 Overuse of intra- articular steroid therapy. 
 It is generally observed that secondary osteoarthritis occurs in the 
younger age groups and is more severe than the primary. Apart from all the features 
of osteoarthritis, secondary osteoarthritis has the features of the corresponding 
aetiological condition. 
  
CLASSIFICATIONS: 
It could be divided into 2 types 
         1. Primary or idiopathic osteoarthritis 
         2. Secondary osteoarthritis 
Primary osteo arthritis results from changes caused by specific 
inflammatory or metabolic conditions while secondary osteo arthritis is caused by 
other conditions that damage cartilage. 
PATHOGENESIS: 
PRIMARY OSTEOARTHRITIS SECONDARY OSTEOARTHRITIS 
1.Usually limited to one or a small 
number of joints. 
May be limited to a small number of joints if 
injury related or may be in joints throughout 
body, if disease related 
2.No specific inflammatory or 
metabolic condition known to be 
associated with arthritis is present. 
Condition that cause damage to cartilage are 
present, such as  -   
 Inherited disease of iron, calcium or 
copper storage such as 
haemochromatosis, 
Hyperparathyroidism or Wilson’s 
disease. 
 Neurologic disorder that result in the 
loss of nerve function. 
 Congenital disease that cause an 
imbalance in the joints.    
3.No history of specific injury or 
trauma. 
History of injury to joints, such as fractures 
and tears or history of trauma to joints, such 
as repetitive heavy lifting. 
 
  
NORMAL ARTICULAR CARTILAGE: 
Normal cartilage has two main components. One is the extra cellular 
matrix, which is rich in collagens (mainly types II, IX and XI) and proteoglycans IX 
mainly aggrecan. Aggrecan is a central core protein bearing numerous 
glycosaminoglycans chains of chondroitin sulphate and keratin sulphate, all capable 
of retaining water. 
The second component consists of isolated chondrocytes, which lie in 
the matrix. The matrix component is responsible for the tensile strength and resistance 
to mechanical loading of the articular cartilage.  
PASSAGE OF NORMAL CARTILAGE TO AGING CARTILAGE: 
Several structural and biochemical changes involving the non 
collagenous component of the matrix occur during aging. These changes alter 
biochemical properties of the cartilage that are essential for the distribution of forces 
in the weight bearing zone. 
Glycosamino glycans are modified qualitatively, they become shorter 
as the cartilage ages.The concentration of type VI keratin sulphate increase during 
aging, to the determent of type IV keratin sulphate. 
These quantitative and qualitative changes in proteoglycan reduce the 
capacity of the molecules to retain water. Thus aging cartilage contains less water, 
which alters the biochemical properties of the cartilage.  
OSTEOARTHRITIC JOINTS 
Osteoarthritic joints have abnormal cartilage and bone, with synovial and capsular 
lesions. 
Macroscopically the most characteristic elements are,  
 Reduced joint space. 
 Formation of osteophytes(protrusion of bone and cartilage) mostly at the 
margins of   joints. 
 Sclerosis of the subchondral bone 
  
SIGNS AND SYMPTOMS: 
              The most common signs and symptoms of osteoarthritis are; 
 Predominant symptom is pain which decreases on walking. The pain is 
poorly localised and dull aching in nature. 
  The patient complains of early morning stiffness which subsides over the 
day after activity.  
 Morning stiffness, which usually lasts no more than 30 minutes. 
 Swelling of the joints  
 Minimal tenderness 
 Restricted range of joint movements 
 Coarse crepitus can be elicited 
 
SITES:  
Common sites of primary osteoarthritis: 
 
 Apophyseal  joint of the  cervical spine 
 Thoraco lumbar spine 
 First carpometacarpal joint 
 Distal interphalangeal joint 
 Patella femoral joint 
 Tibio femoral joint 
 First metatarsalphalangeal joint 
 
Intermediate sites: 
 
 Acromio clavicular joint 
 Hip joint 
Uncommon sites: 
 Shoulder joint 
 Elbow joint 
 Wrist joint 
 Metaphalangeal joint 
 Ankle joint 
DIAGNOSTIC CRITERIA: 
Formal criteria helpful for diagnosis of osteoarthritis in synovial joints: 
 Age greater than 60 years. 
 Pain and swelling in knee joint 
 Morning stiffness lasting less than 30 minutes. 
 Crackling sensation (crepitus) present in knee joint. 
 Joint- line or periarticular tenderness.  
 Bony swelling (osteophyte) around joint margins. 
 Restricted joint movements 
DIAGNOSIS: 
There is no single sign, symptom or test result that allows a definitive 
diagnosis of osteoarthritis. Instead the diagnosis is based on a consideration of several 
factors, including the presence of the characteristic signs and symptoms of 
osteoarthritis, physical examination and the results of laboratory tests and x-rays. 
COMPLICATIONS OF OSTEOARTHRITIS: 
The major complications of osteoarthritis of knee 
 Joint deformities 
 Subluxation  
 Ankylosis  
 Intra- articular loose bodies 
Life style effects include 
 Depression 
 Anxiety 
 Feelings of helplessness 
 Limitation  of  daily activities 
 Job limitations 
 
  
  
 
 
 
 
 
 PROPERTIES OF  
    TRIAL  DRUGS 
  
            – NATURAL RED SULPHIDE OF MERCURY  
          (Cinnabar) 
Potency- Hot 
Action -         ( Alterative ) 
General Properties 
 
                              
                     –      
                            
                      ’’ 
                                 
                   –      
                          
                      ’’ 
-                    
Uses: 
  It cures diarrhoea, pyrexia, delirium, urticaria, tuberculosis, scabies,  
insect  bites, syphilis, skin diseases, throbbing pain(soolai) and vatha diseases.         
       - SODIUM BIBORATE 
Action:  
  Refrigerant  
   Diuretic 
   Emmenagogue 
   Lithontriptic 
   Antiseptic 
Taste: Sweet With Astringent 
General Properties 
                              
                      -       
                             
                     . 
-                    
Vengaram is indicated for eight type of ulcers, dental diseases, urinary tract 
infections, kabha disorders, delirium. 
     
Botanical name:   Vigna mungo (Linn) hepper 
Family:   Fabaceae 
Part used :   Seed, root 
Organo leptic characters 
Taste : sweet 
Potency: cold 
Division : sweet  
Action : 
 Demulcent 
 Refrigerant  
 Aphrodisiac  
 Galactagogue 
 Nervine tonic 
 Nutritive 
General Properties 
 
                               
                        –        \ 
                         
                . 
(                ) 
 
It gives strength to the waist of women,it acts as good nutrient and refrigerant to body. 
Chemical constituents:   
Black gram contains tryptophan, methionine and leaves contain saponin. 
 
 
 
  
        
 
Botanical name:  Pavonia zeylanica.Cav 
Family :   Malvaceae 
Part used :   Samoolam ( whole plant) 
 
Organoleptic characters : 
Taste   :   Pungent  
Potency :   Cold  
Division :   Sweet  
General Properties 
   
                              
                        –         
                            ! 
                    . 
-                
 
It is indicated for osteomyelitis, pitha disorders, febrile conditions. 
 
Chemical constituents:  
 
Ephedrine and pseudoephedrine constitute the major alkaloids from the 
aerial parts of the plant, which also show traces of sitosterol and palmitic, stearic and 
hexacosanoic acids. The flavones: 5,7-dihydroxy-3-isoprenyl flavone (1) and 5-
hydroxy-3-isoprenyl flavone (2), β-sitosterol and stigmasterol have been isolated from 
the plant. The analgesic alkaloid (5′-Hydroxymethyl-1′-(1,2,3,9-tetrahydro-pyrrolo 
[2,1-b] quinazolin-1-yl)-heptan-1-one) has also been found. 
 
  
RICINUS COMMUNIS 
 
      - General Properties 
  
                                
                    -        
                                 
                   
-            
 
             
 
Botanical name:  Ricinus communis 
Family :    Euphorbiaceae  
Part used :   Root , leaf seed. 
 
Organoleptic characters : 
Taste :  bitter 
Potency :  hot  
Division :  pungent 
Action : 
        – Anti vaatha. 
 
The Root of Ricinus communis is used as an important ingredient inall  
anti vatha  decocotion and anti vatha oil preparations like vathanth thylum, poothika 
thylum, chukka thylum.  
 
Chemical constituents :  
Ricintriglyceride, stigmasterol,ricinine,gallic acid,aleuritic acid,ethyl 
brevifolincarboxylate,9-hydroxytridecyl docosanoate, lupeol,luteolin ,palmitic 
acid,octacosanol,and octadecane .  
  
        
 
Botanical name:  Aconitum heterophyllum 
Family:  Ranunculaceae  
Part used :  Root 
 
General Properties 
                               
                        –         
                                  
                 !   . 
-                
 
It is indicated for intermittent fever , diarrhoea, cough, vomitting 
 
Organoleptic characters : 
 
Taste : Bitter 
Potency : hot  
Division : pungent 
Action : 
          -  Stomachic 
         –  Astringent 
           - Aphrodiasic 
         –  Tonic 
            -Antiperiodic 
          - febrifuge 
 
Chemical Constituents: 
Atisine hetisine, heterophyllinine, Heterophylidine, hetidine, atidine, 
pseudo aconitine. 
  
        
 
Botanical name: Alpnia galanga 
Family :   Zingeberaceae 
Part used :   Root 
 
Organoleptic characters : 
Taste : pungent  
Potency : hot 
Division : pungent 
Action : 
            - Expectorant  
          – Febrifuge  
         - Stomachic 
 
General Properties 
                                
                         –          
                            
                     . 
-              
 
Vatha diseases, eczema, head ache, cough,cold, febrile conditions, and 
kabha diseases were indicqated for alpinai galangal. 
 
Chemical constituents:  
Root contains campheride, galangin and alpinin. Rhizome contains 
volatile essential oil, it has 48% of methyl cinnamate, 20-30 cincole, camphor and 
alpha – pinene. 
                 
 
Botanical name:  Tragia involucrata 
Family :   Euphorbiaceae 
Part used :   Root 
 
Organoleptic characters : 
Taste :Bitter  
Potency : hot 
Division : pungent 
General Properties 
 
                                
                      –        
                              
                     . 
                                                       -                
 
Siru kanchori  root indicated for Cardiac asthma. Fever due to all three 
humours derangements, eczema, scabies, vatha, thirst.  
      – Impura Sodium Chloridium 
Action :  
Laxative  
  Diuretic 
  Carminative 
  Stomachic  
General Properties 
 
                                
                         –         
                                  
                  . 
 
                                    
                       –         
                           
                    .  
-                    
Eight type of ulcers, derangemants of three humours and vatha discomfortrs, delirium, 
thirst, dysponea, painful conditions, 
  
               
 
Botanical name:  Asparagus racemosus 
Family :  Alliaceae 
Part used :   Leaf, Tuber 
 
Organoleptic characters : 
Taste : Pungent  
Potency : Hot 
Division : Pungent 
 
Action : 
           -  Nutritive 
           -  Demulcent 
            -  Galactogouge 
            -  Aphrodisiac 
         -  Antispasmodic 
General Properties 
 
                                 
                        -       !   
                                   
                    . 
-                
 Thanneer vittan kizangku is indicated for Diabetes, chronic fever, rickets, 
sexually transmitted diseases. 
 
Chemical constituents:  
   It contains saachrine, mucilage and Asparagamine. 
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  PRECLINICAL 
           
             STUDY 
  
Form B (per rule 8(a) 
              APPLICATION FOR PERMISSION FOR ANIMAL EXPERIMENTS 
 
Application to be submitted to sent either to the CPCSEA (address in form A 
above) or Institutional Animal Ethics Committee (IAEC) 
 
Part A 
*1. Name and address of establishment : 
                                 
                                 National Institute of Siddha, 
                                 Tambaram Sanatorium, 
                                 Chennai- 47. 
                                                                                               
*2. Registration number and date of registration 
                                 
                                 1248/ac/09/CPCSEA 
 
3. Name, address and registration number of breeder from which animals 
acquired (or to be acquired) for experiments mentioned in parts B & C 
 
    King Institute, Guindy, Chennai 
 
4. Place where the animals are presently kept (or proposed to be kept) 
                                
                                 Animal house, NIS 
 
5. Place where the experiment is to be performed (Please provide CPCSEA 
Reg.Num) 
 
                                  Pharmacology Laboratory, NIS.  1248/ac/09/CPCSA  
 
6. Date on which the experiment is to commence and duration of experiment 
 
                                      February - 2012, 6 months 
 
7. Type of research involved (Basic Research/Educational/Regulatory) 
 
                                         M.D   Dissertation 
 
Signature 
 Date: 
 
Place:                                                                          Name and designation of    
                                                                                     Investigator 
*Applicable only for application to be submitted to CPCSEA 
PART B 
Protocol form for research proposals to be submitted to the 
committee/Institutional Animal Ethics Committee, for new experiments or 
extensions of ongoing experiments using animals other than non-human 
primates. 
 1. Project / Dissertation / Thesis Title:  
 
Pre clinical and clinical  study on  AZHAL KEEL VAYU  (OSTEO ARTHRITIS)  
and the drug of choice is SARVA NOI LINGA CHENDURAM (int) & 
MAASHA THYLUM(ext) 
 
2. Principal Investigator / Research Scholar / Research Guide / Advisor  
 
Guide 
 
a. Name                   Prof.  Dr.K.Manickavasakam MD (S)., 
     
b. Designation        Head of the department and Director i/c of NIS 
 
c. Dept / Div/ Lab    Dept  of Maruthuvam  
   
d. Telephone No.    9444249798 
 
e. Experience          26 years  
 
 
 
3. List of names of all individuals authorized to conduct procedures under 
this proposal 
 
a. Name                 
b. Address            
c. Experience        
Research Scholar:  
a. Name:               Dr R.RADHA KRISHNAN 
b. Address:          2
nd
  yr , Dept of Maruthuvam,  
                              National Institute of Siddha, 
                              Chennai -47. 
 
4. Funding source with complete address (Please attach the proof) 
 
                                              Self 
 
5. Duration of the project 
 
a. Number of months                        :  Three months 
 
b. Date of initiation(Proposed)         : February, 2012 
 
c. Date of completion (Proposed)    : August, 2012 
 
 
 
 
6. Detailed study plan may be given (Not more than one page) 
 
                                       Enclosure 1 
 
 
7. Animals required 
 
a. Species/Common name  : Rat, Mice 
 
b. Age / weight / size : 6 weeks. Rat-150-200gms, Mice-20-25 gms. 
 
c. Gender: Both 
 
d. Number to be used (Year-wise breakups and total figures needed to 
     be given ) 
     Mice: 20 
     Rats: 40 
          
        Acute toxicity (WHO guidelines, 1993) 
 
S.No Group No of mice 
1 Vehicle control (  radish juice ) 10  (5 male, 5 female) 
2 Toxic dose (10X therapeutic dose) 
(Single dose) (2.34mg) 
10  (5 male, 5 female) 
 
Sub acute  toxicity studies : 3 months 
 
e. Number of days each animal will be housed: 1 week 
 
8. Rationale for animal usage 
 
a. Why is animal usage necessary for these studies? 
                               
                                Preclinical toxicity studies are generally carried out using animal 
models. So animals are required to conduct toxicity studies. 
 
b. Why are the particular species selected required? 
 
                               Standard protocols recommends the use of rodents for the toxicity 
studies. 
 
S.No Group No of Rats 
1 Vehicle control (  Radish juice  ) 10  (5 male, 5 female) 
2 1XTherapeutic dose(2.34mg) 10  (5 male, 5 female) 
3 5XTherapeutic dose(11.7mg) 10  (5 male, 5 female) 
4 10XTherapeutic dose(23.4mg) 10  (5 male, 5 female) 
c. Why is the estimated number of animals essential? 
 
The recommended guidelines requires the estimated number of animals 
 
d. Are similar experiments conducted in the past? If so, the number of animals 
used and results obtained in brief. 
 
                                 No 
 
 
e. If yes, why new experiment is required? 
 
                                 Not applicable 
 
f. Have similar experiments been made by any other organization 
agency? If so, their results in your knowledge. 
 
                                        NO  
                                    
 
 
9. Description the procedures to be used. 
List and describe all invasive and potentially stress full non-invasive 
procedures that animals will be subjected to in the course of the experiments. 
 
           
Furnish details of injections schedule 
 
Substances: 
Doses :                                   Enclosure 2 
Sites : 
Volumes : 
Blood withdrawal 
             Volumes: 
              Sites : 
              Radiation (dosage and schedules): 
 
 
 
10. Please provide brief descriptions of similar studies from invitro / invivo (from  
other animal models) on same/similar test component or line of research. 
If,enough information is available, justify the proposed reasons. 
 
                                              Not  applicable 
 
 
11. Does the protocol prohibit use of anesthetic or analgesic for the conduct of 
painful procedures (any which cause more pain than that associated 
with 
routine injection or blood withdrawal)? If Yes, explanation and justification 
                                               Not applicable 
 
 
12. Will survival surgery be done? 
                                     
                                              Not applicable 
 
 
If Yes, the following to be described. 
 
                                                
a. List and description of all such surgical procedures (including methods of   
asepsis) 
                                              Not applicable 
 
 
 
b. Names, qualifications and experience levels of operators 
 
                                               Not applicable 
 
 
c. Description of post-operative care 
 
                                                   Not applicable 
 
 
d. Justification if major survival surgery is to be performed more than once 
on a single individual animal. 
 
                                                     Not applicable 
 
 
 
13. Methods of disposal post-experimentation 
 
a. Euthanasia (Specific method): 
 
                                         Excessive anaesthesia 
 
b. Method of carcass disposal:  
Carcass will be packed in bio-hazardous bag and disposed through G.J.Multi 
clave private limited, GST road, Tambaram sanatorium, Chennai-47. 
c. Rehabilitation:   -------- 
 
 
14. Animal transportation methods if extra-institutional transport is envisaged                      
                           Air conditioned vehicle 
 
15. Use of hazardous agents (use of recombinant DNA-based agents or 
potential human pathogens requires documented approval of the Institutional   
Biosafety Committee (IBC). For each category, the agents and the biosafety  level 
required, appropriate therapeutic measures and the mode of disposal of  
contaminated food, animal wastes and carcasses must be identified) 
 
(a) Radionuclides 
 
 
(b) Microorganisms / Biological infectious Agents 
 
 
(c) Hazardous chemicals or drugs 
 
 
(d) Recombinant DNA 
 
 
(e) Any other (give name) 
 
If, your project involved use of any of the above, attach copy of the minutes of    
IBC granting approval. 
                        
                                               Not applicable 
 Investigator's declaration. 
 
 
1. I certify that I have determined that the research proposal herein is not 
unnecessarily duplicative of previously reported research. 
 
2. I certify that, I am qualified and have experience in the experimentation on  
animals. 
 
3. For procedures listed under item 11, I certify that I have reviewed the 
pertinent scientific literature and have found no valid alternative to any 
procedure described herein which may cause less pain or distress. 
 
4. I will obtain approval from the IAEC/CPCSEA before initiating any 
significant  changes in this study. 
 
5. Certified that performance of experiment will be initiated only upon review 
and  approval of scientific intent by appropriate expert body (Institutional 
Scientific  Advisory Committee / funding agency / other body (to be named). 
 
6. Institutional Biosafety Committee's (IBC) certification of review and 
concurrence will be taken (Required for studies utilizing DNA agents of 
human pathogens). 
 
7. I shall maintain all the records as per format (Form D) 
8. I certify that, I will not initiate the study unless approval from CPCSEA 
received in wiring. Further, I certify that I will follow the recommendations of  
CPCSEA. 
 
9. I certify that I will ensure the rehabilitation policies are adopted. 
 
 
 
 
 
  Signature 
 
 
Date:           Name of Investigator 
 
 
                                              
 
 
 
                                                      
  
CERTIFICATE 
 
 
This is certify that the project title………………………………………………….. 
…………………………………………………………………………………………
…..has been approved by the IAEC. 
 
 
 
Name of Chairman/Member Secretary IAEC:       Name of CPCSEA nominee: 
 
 
 
Signature with date 
 
 
 
Chairman/Member Secretary of IAEC:                                 CPCSEA nominee: 
 
 
 
 
 
(Kindly make sure that minutes of the meeting duly signed by all the participants 
are maintained by Office )                     
                             
   
 
 
 
 
 
 
 
 
 
 
 
 
   
  
Enclosure1       
 
            SARVA NOI LINGA CHENDURAM (int) (Anuboga Vaithiya Navaneetham 
Part IV) and  maasha thylum Vaithiya Sinthamani - Sigicha Rathina deepam  is 
practiced in siddha system of medicine for Azhal Keel vayu (sabapahti kaiyedu and 
siddha maruthuvam pothu ) is one of the 10 types of keelvayu   which is correlate 
with osteo arthritis (DAVIDSON’S PRINCIPLES & PRACTICE OF MEDICINE, 
2002) having the symptoms of Pain and swelling knee joints, morning stiffness& 
restricted movements in the all joints especially knee joints, body pain, fatigue, 
dryness of the tongue, Fever, Difficulty in walking etc. 
                                             
               When reviewing literature so for no scientific evaluation were carried out for 
its toxicity pre-clinically .So in our present investigation we aimed to conduct acute 
and long term toxicity studies. 
 
                  Acute and long term study are designed as per WHO guidelines, because 
WHO has specially given the guidelines for conducting toxicity studies for 
Traditional medicine. 
 
                 According to WHO “Traditional Medicine includes a plant derived material 
or preparation with therapeutic or other human health benefits which contains either 
raw or processed ingredients from  one or more plants .In some traditions, materials of 
inorganic or animal origin may also be present”. 
 
                 The trial drug is clinically prescribed for 48 days. Hence long term study is 
designed for 3 months as per   WHO guidelines for traditional medicine. 
 
Enclosure: 2 
Acute toxicity (WHO guidelines, 1993) 
 
S.No Group No of mice 
1 Vehicle control (  raddish juice ) 10  (5 male, 5 female) 
2 Toxic dose (10X therapeutic dose) 
(Single dose) (23.4mg) 
10  (5 male, 5 female) 
 
The animals will be monitored for behavioral parameters like alertness, visual 
placing, stereotypy, passivity, grooming, restlessness, irritability, fearfulness, 
spontaneous activity, reactivity, touch response, pain response for the first 4 hours 
after drug administration. Body weight of the animal will be monitored at weekly 
interval. The animals will be monitored for mortality for 14 days. The animals that die 
within this period will be subjected to necropsy. All animals will be weighed and 
sacrificed on the 15
th
 day after administration and then the vital organs including 
heart, lungs, livers, kidneys, sex organs and brain will be grossly examined. 
 
Sub acute  toxicity studies:  
 
 
 
. 
 
 
   
 
 
Duration of drug administration : 3 months  
 
All rats were observed for apparent signs of toxicity or behavioral alterations during 
the experimental period. At the end of each experiment, the rats were fasted 12 hours 
and then anesthetized with ether. Blood will be collected from a  Jugular vein for 
hematological study. The serum will be separated and the levels of glucose, blood 
urea nitrogen (BUN), creatinine, total protein, albumin, total bilirubin, direct bilirubin, 
alkaline phosphatase (ALP), serum glutamate, oxaloacetic transaminase (SGOT) and 
serum glutamic pyruvic transaminase (SGPT) will be measured. After the blood 
collection, the animals were sacrified for tissue examinations. The following organs 
will be weighed, examined and then fixed in 10% buffered formaldehyde solution for 
histopathological observations: heart, lungs, livers, kidneys, stomach, brain and sex 
organs. 
 
 
S.No Group No of Rats 
1 Vehicle control (  radish juice) 10  (5 male, 5 female) 
2 1XTherapeutic dose(2.34mg) 10  (5 male, 5 female) 
3 5XTherapeutic dose(11.7mg) 10  (5 male, 5 female) 
4 10XTherapeutic dose(23.4mg) 10  (5 male, 5 female) 
For IAEC/CPCSEA usage) 
 
Proposal number: 
 
Date first received : 
 
Date received after modification (if any) : 
 
Approval date : 
 
Expiry date : 
 
Name of Chairman /Member Secretary IAEC :              Name of CPCSEA 
nominee: 
 
Signature with date : 
 
Chairman /Member Secretary IAEC:                                               CPCSEA 
nominee: 
 
 
 
 
 
 
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
  CLINICAL  STUDY 
  
MATERIALS AND METHODS  
Title:   
      Preclinical and Clinical study on AZHAL KEELVAYU (OSTEOARTHRITIS)    
       and the drug of choice is SARVA NOI LINGA CHENDURAM   (Internal) &      
                    MAASHA THYLAM [ ulunthu thylum] (External). 
 
OBJECTIVE :  
 
Primary objective :   
 
To evaluate the therapeutic efficacy of siddha formulations  SARVA 
NOI LINGA CHENDURAM (Internal) &Mashaa thylum[ulunthu thylum] (External) 
for reducing pain in the treatment of  AZHAL KEEL VAYU (OSTEOARTHRITIS). 
 
Secondary objective:   
 To evaluate the safety profile ( Acute, long term toxicity studies) of this drug. 
 To study the siddha cofactors  such as age, sex, dietary influence. 
 
STUDY DESIGN & CONDUCT OF STUDY. 
 
Study type : An open clnical tial 
Study place : OPD and IPD of Ayothidass pandithar hospital, National 
 Institute  of   siddha, Tambaram sanatorium, Chennai-47. 
Study period : 12 months 
Sample size  : 40 patients  
TREATMENT: 
     
 MEDICINE  NAME : 
 
               1. SARVA NOI  LINGA CHENDURAM(internal) (5) 
                          Ref : Anuboga Vaithiya Navaneetham , Part 4, 
      Hackim PA. Mohammed Abdullah Sayubu  , Edition:  pg no 52 &53  
                2. MAASHA  THYLUM [ ulunthu thylum ] (external) (6) 
                              Ref:  Vaithiya Sinthamani ( Sigicha Rathina deepam )   Pg no:202 
      C.Kannusamipillai  Edition 2007     
     DOSAGE : 130 mgs twice a day. 
METHOD OF DRUG ADMINISTRATION: 
Given for 7 days followed by a break of 5 days. Again the medicine is 
given for 7 days followed by a break of 5 days. Likewise two more times are repeated. 
ADJUVANT: Honey (after food) 
COURSE:    48 days 
DURATION OF TREATMENT: 28 days 
DIET  RESTRICTION: 
Every  first day of break( redieting) starts with head bath with the paste 
of Ajowan seeds and cow’s milk and diet free of salt, tamarind ,etc  noted in the form 
IV D (Dietary advice form). Dietary advice is strictly followed during the period of 
drug administration as well as redieting period. During redieting period roasted salt 
intake is recommended. 
 
MAASHA THYLUM (External) 
 
DOSAGE:  Sufficient quantity 50 ml 
       Applied externally over the affected parts. 
 
SUBJECT SELECTION 
                 
 As and when patients reporting at OPD of Ayothidass  Pandithar  Hospital 
with symptoms of inclusion criteria will be subjected to screening test and 
documented using screening  proforma . 
 
INCLUSION CRITERIA 
 
 Age :30-60Yrs 
 Sex – Both sex 
  Signs and Symptoms of pain ,swelling of knee joints,  stiffness & restricted 
movements 
 Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 48days but can opt out of the 
trial of his/her own conscious discretion. 
 Patients who are willing   to take  radiological investigation (X RAY KNEE 
JOINT)  and provide blood for lab investigation. 
 EXCLUSION CRITERIA 
 
 Rheumatoid arthritis 
 Gouty arthritis 
 Fractures 
 Tuberculosis 
 Diabetes mellitus 
 Hypertension 
 Viral fever ( Chikun gunya) 
 Any other serious illness. 
 Cardiac disease 
 Renal disease 
 Patients taking any NSAID 
 Trauma 
 
WITHDRAWAL CRITERIA 
 
 Intolerance to the drug & development  of adverse reactions during drug 
trial. 
 Poor patient compliance & defaulters. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Increase in severity of symptoms 
 
TEST & ASSESSMENTS 
 
A. CLINICAL ASSESSMENT 
       SIDDHA ASSESSMENT 
 
B. ROUTINE INVESTIGATION 
C. SPECIFIC INVESTIGATION 
  
CLINICAL ASSESSMENT(12) 
 
1. Pain of knee joints(Left/Right/Both]   
2. Swelling of knee joints 
3. Warmth over the knee joints.    
4. Stiffness of the knee joints. 
5. Crepitations of the knee joints 
6. Instability of the knee joints. 
7. Joint  deformity 
8. Restricted movements of the knee joints 
9. Muscle weakness, wasting over the knee joint. 
                 
 
SIDDHA ASSESSMENT 
 
1.Thinai : 
 Kurinchi (hill areas) 
 Mullai ( forest ) 
 Marutham ( fertile land ) 
 Neidhal ( coastal area ) 
 Palai ( desert ) 
2. Paruva Kalam ( season )  
 Karkaalam 
 Koothir kaalm 
 Munpanikaalm 
 Pinpani kaalam 
 Ilavenil kaalam 
 Muthuvenil kaalam 
3. Poripulankal: 
 Mei (Skin etc) 
 Vaai (Tongue etc) 
 Kan (Eye etc) 
 Mooku (Nose etc) 
 Sevi (Ear etc) 
  
4.Kanmedriyamand Gnanenthiriyam: 
 Vaai (Buccal cavity) 
 Kaal (Lower limbs) 
 Kai (Upper limbs) 
 Eruvaai (Anorectal region) 
 Karuvaai (Uro-genital region) 
       5. Ezhu Udalkattugal: 
 Saram 
 Senneer 
 Uoon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam /suronitham 
6.Ennvagaithervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
- Neerkuri 
 
- Neiku 
 
SIDDHA PARAMETERS 
         Malam 
 
         Moothiram 
B .  ROUTINE INVESTIGATION 
 Hb(gm/dl) 
 Total WBC Count(cells/cumm) 
 DC-  Polymorphs(%) 
 Lymphocytes(%)  
 Eosinophils (%) 
 Monocytes (%) 
 Basophils(%)  
 Total RBC count million cells/cumm) 
 ESR(Men 6-12mm/hr  Women 7-18 mm/hr) 
  B.glucose (mg/dl)  
LIPID PROFILE 
 Serum cholesterol(mg/dl)- 
  HDL cholesterol(mg/dl)- 
  LDL cholesterol(mg/dl)- 
 VLDL cholesterol(mg/dl)- 
 Serum triglycerides  (mg/dl)-    
 KIDNEY FUNCTION TEST 
  B.urea(mg/dl)  
 S. total creatinine (mg/dl) 
LIVER FUNCTION TEST 
 S.total bilirubin(mg/dl)  
 S.direct bilirubin (mg/dl) 
 S. indirect bilirubin (mg/dl) 
 SGOT(u/l) 
 SGPT (u/l) 
 S.alkaline phosphataseu/l)  
 S.total protein(g/dl)  
 S. albumin (g/dl) 
 S.globulin (g/dl) 
 S. calcium (mg/dl) 
 S. phosphorous (mg/dl) 
  
URINE EXAMINATION  
  Albumin 
 Sugar (Fasting & post prandial) 
 Deposits  
 Bile salts  
 Bile pigments 
 Urobilinogen 
MOTION - Ova Cyst             SPUTUM  - AFB 
D.SPECIFIC INVESTIGATION 
ASO TITRE, RA FACTOR, CRP TITRE 
OTHER INVESTIGATIONS     
X RAY FOR  KNEE JOINTS( BOTH AP/ LAT VIEW) 
STUDY ENROLLMENT: 
 In this clinical trial patients reporting at NIS OPD with the clinical symptoms 
of  pain& swelling of knee joints, morning stiffness& restricted movements 
will  be examined clinically for enrolling in the study based on the inclusion 
and exclusion criteria.  
 The patients in this study will be  be  informed(Form-IVC) about theobjective 
of the  study, trial drug, possible outcomes will in their own language and 
terms understandable to them. 
 After ascertaining the patient’s  willingness, informed consent would be 
obtained in writing from them in the consent form .(Form- IVA) 
 All these patients will be given unique registration card in which patients’ 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. so as to report  easily and any adverse reactions arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
will be recorded in the prescribed Proforma in the history and clinical 
assessment forms separately. Screening Form- I will be filled up; Form I-A,  
Form –II and Form –III will be used for recording the patients’ history, 
clinical   examination of symptoms and  signs and laboratory investigations 
respectively. 
 Patients would be advised to take the trial drug and appropriate dietary advice 
(Form IV-D) would be given according to the patients’ perfect understanding. 
 
CONDUCT OF THE STUDY: 
  Before starting the course purgation will be  with the OP medicine 
Agasthiar Kuzhambu 130 mg od with ginger juice early morning in empty stomach. 
 
            The trial drug  SARVA NOI LINGA CHENDURAM (Internal)  is 
given for 7 days followed by a break (redieting) of 5 days. Again the medicine is will 
be  for 7 days followed by a break of 5 days. Likewise the medicine is given till the 
end of the course . 
 
             Every  first day of break( redieting) starts with head bath with the paste 
of Ajowan seeds and cow’s milk and diet free of salt, tamarind ,etc .. noted in the 
form IV D (Dietary advice form). Dietary advice is strictly followed during the period 
of drug administration as well as redieting period.During redieting period roasted salt 
intake is recommended. 
 
            The trial drug  MAASHA  THYLUM[ ulunthu thaylum] (External) 
will be  given continuously for 48 days for external application 
            For OP patients ,they should visit the hospital once in 12  days.  At 
each clinical visit clinical assessment is done and prognosis is noted.  
            For IP patients clinical assessment is  done daily and prognosis is 
noted. 
            Laboratory investigations & radiological  investigation are done 0 day 
and 24th  & 48 th day of the trial  for both OP & IP patients. 
 
             For IP patients, who is not in a situation to stay in the hospital for a 
long time is advised to attend the OPD for the continuation of the treatment. After the 
end of the treatment also, the patient is advised to visit the OPD  for another 2months 
for follow-up. If any trial patient who fails to collect the trial drug on the prescribed 
day but wants to continue in the trial from the next day or two, he/ she will be 
allowed, but defaulters of one week and more will not be allowed to continue and be 
withdrawn from the study with fresh case being included.         
  
DATA MANAGEMENT 
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification. Whenever study patient visits 
OPD during the study period, the respective patient file will be taken and 
necessary recordings will be made at the assessment form or other suitable 
form. 
 The screening forms will be filed separately. 
 
 The Data recordings will be monitored for completion by HOD and adverse 
event by  Sr.Research Officer (Statistics). All forms will be further scrutinized 
in presence of Investigators by Sr.Research Officer (Statistics) for logical 
errors and incompleteness of data to avoid any bias. No modification in the 
results is permitted for unbiased reports. 
 
 STATISTICAL ANALYSIS: 
All collected data will be entered into the computer and manually 
cross-checked the correctness of the data entry. The clinical symptoms and pain scale 
will be analysed by comparing the two point of data(before and after treatment) paired 
test and chi-square test will be employed to study the efficacy of treatment. Futher, 
the effect of age and sex will also be analysed. 
  
OUT COME: 
1.PRIMARY OUTCOME 
Outcome is pain mainly assessed by Universal Pain assessment scale-Numeric 
Rating Scale (13) before and after treatment 
Numeric Rating Scale (0-10) for pain : 
0        No pain 
1-3    Mild pain  (Nagging, Annoying, Interfering little with ADLs) 
4-6    Moderate pain (Interferes significantly with ADLs) 
7-10   Severe pain (Disabling, unable to perform ADLs) 
(ADLs-Activities of daily living) 
                                    
 
National institute of health, Warren Grant Magnuson Clinical care, pain 
intensity instrument – july 2003 
 
2.SECONDARY OUTCOME 
Secondary outcome is assessed by following parameters before and after treatment. 
      1. Reduction in other clinical symptoms 
      2. Restricted movement assessment scale. 
 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: 
If the trial patient develops any adverse reaction, he/she would be 
immediaetly withdrawn from the trial and proper management will be given in OPD 
of National institute of siddha. 
  
ETHICAL ISSUES  
 
1. To prevent any infection, while collecting blood sample from the patient, 
only disposable syringes, disposable gloves, with proper sterilization of lab 
equipments will  be used.                         
2. No other external or internal medicines will be used. There will be no 
infringement on the rights of patient.    
       3. The data collected from the patient will be kept confidentially. The patient 
will be informed about the diagnosis, treatment and follow-up.  
4. After the consent of the patient (through consent form) they will be enrolled 
in the study.  
5. Informed consent will be obtained from the patient explaining in the 
understandable language to the patient. 
6. Treatment would be provided free of cost.  
     7. In conditions of treatment failure, adverse reactions, patients will be given             
alternative treatment at the National Institute of Siddha with full care throughout the 
end. 
     8 .The patients who are excluded (as per exclusion criteria) are given proper 
treatment at National Institute of Siddha.   
 
  
ASSESSMENT FORM 
 
FORM I   SCREENING AND  SELECTION PROFORMA 
 
FORM I   A HISTORY PROFORMA ON ENROLLMENT 
 
FORM ll  CLINICAL ASSESSMENT ON ENROLLMENT 
 
FORM ll A  CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
 
FORM lll    LABORATORY INVESTIGATION ON ENROLLMENT AND  
 
      CONCLUSION OF TRIAL 
FORM IV A   DRUG COMPLIANCE FORM  
 
FORM IV B  INFORMATION SHEET  
 
FORM IV C   CONSENT FORM 
 
FORM IV D DIETARY ADVICE FORM 
 
 
FORM IV E   WITHDRAWAL FORM 
 
FORM IV F   ADVERSE REACTION FORM 
  
  
 
 
 
 
 
       PREPARATION   
                        OF  
        TRIAL  DRUGS  
  
  PREPARATION OF THE TRIAL DRUGS  
INTERNAL DRUG:  SARVA NOIA LINGA CHENDURAM 
     REFERENCE: Anuboga vaithiya navaneetham, part 4, page no 53&54 
INGREDIENTS: 
 Purified lingam - 1palam(35 gms)   
 Purified vengaram - 4 palam (140gms 
 
METHOD OF PURIFICATION: 
 
 Lingam (natural red sulphide of mercury, cinnabar): 
 
Soak it in lime juice for  2 hours. 
 
 Vengaram ( Sodium Biborate, Borax  ) : 
 
 Fry the borax well till the water content in it dried 
 
PREPARATION 
 
 Purified lingam is powdered first. 
 
 Then the purified vengaram is  placed in a mud plate is subjected to  
mild flame until it gets melted, 
 
 Powdered lingam is then added little by little to the melted vengaram 
 
 Stir the above  said the mixture until it solidifies  
 
 Then the solidified mixture is allowed to cool 
 
 Finally, powder the solidified mixture and preserve it in a glass 
container. 
 
DOSAGE : 130 mgs twice a day After food  
  ADJUVANT: Honey 
  
                                                      
             
                    
 
                    
                         
                       
  
MAASHA  THYLUM [ ulunthu thylum] (External.) 
Ref: Vaithiya Sinthamani  ( Sigicha Rathina deepam )   Pg no:202       
                                                                          
INGREDIENTS: 
 
 Ulunthu -1400 gm - I                For decoction  
 Sitramutti 1400 gm –II  
 
 Ulunthu   - 105 gm -III 
 Aamanakku vaer - 105 gm -IV 
 Athividayam  - 105 gm -V 
 Sitrarathai  - 105 gm -VI 
 Sirukainjchori vaer - 105 gm   -VII 
 Inthuppu   - 105 gm -VIII 
 Thanneer vittan kizangu -105 gm   -IX 
 
METHOD OF PREPERATION: 
 
 Prepare decocotion from ingredient I &  II ( use 21.4 ltr water boiled the 
mixture is until it reduce half of the total ltrs) 
 Half of the quantity of decoction is used paste  for prepration with ingredients 
III to  IX 
 The remaining half of the quantity of  decocotion is mixed with gingeely oil  
( gingely oil  - 5.36 ltr ) and subjected to boil in mild flame 
 Add the paste to the boling oil, stir it well until it reaches the paste conisitency 
i.e mezugu patham 
 Then preserve it in the glass container. 
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    Results 
  
OBSERVATION AND RESULTS 
1.Gender distribution 
2.Age Distribution 
3. Gunam distribution 
4. Kaalam distribution 
5. Dietary habits 
6. Seasonal variation 
7. Thinai 
8. Socio-economic Status 
9. Occupational status 
10. Precipitating factors 
11. Chronicity of illness 
12. Clinical features 
13. Disturbances in kanmenthiriyam 
14.Disturbances in vatham 
15. Disturbances in pitham 
16. Disturbances in kabam 
17. Udal Kattugal 
18. Ennvagai Thervugal 
19.Kosangal 
20. Naadi 
21. Neikkuri 
22. Involvement of knee joints 
23. Outcome measurements 
24. Results after treatment 
  
1.GENDER DISTRIBUTION 
 
 
 
 
 
 
Inference: 
 
         Among the 40 cases the prevalence of the disease was found to be higher in 
females. i.e 70 %(28cases) and 12 cases (30%) were in male. 
  
30% 
70 % 
0 
10 
20 
30 
40 
50 
60 
70 
80 
MALE FEMALE 
GENDER 
GENDER NO OF CASES PERCENTAGE(%) 
MALE 12 30 
FEMALE 28 70 
TOTAL 40 100 
2.AGE DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
 
Inference: 
Among the 40 cases 6 cases were found in between  the age group of 30 and 
40. Then 11 cases (27.5%) were between 41-50, The prevalence of the disease was 
found to be higher in the age group 51-60 years. i.e, 23 cases(57.5%) 
 
3.GUNAM DISTRIBUTION 
          GUNAM NO OF CASES PERCENTAGE(%) 
SATHUVA GUNAM - - 
RASATHAM GUNAM 40 100 
THAMO GUNAM - - 
TOTAL 40 100 
Inference: 
All the 40 cases (100 %) were found to posses rasatha gunam 
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AGE 
AGE NO OF CASES PERCENTAGE(%) 
30-40 06 15 
41-50 11 27.5 
51-60 23 57.5 
TOTAL 40 100 
4.KAALAM DISTRIBUTION 
 
           
 
Inference: 
The prevalence of the disease was found to be higher in the age group 34-66 
years. i.e, pitha kaalam 38 cases(95%).  Only 5% age group in 0-33 years,i.e vatha 
kaalam. 
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KAALAM NO OF CASES PERCENTAGE(%) 
VATHA KAALAM 
(up to 33 years) 
2 5 
PITHA KAALAM 
(34-66years) 
38 95 
KABA KAALAM 
(above 66 years) 
- - 
TOTAL 40 100 
5.DIEATARY HABITS 
 
     
Inference: 
Among the 40 cases 32 cases(80%) were Non vegetarians and 8 cases(20%) 
were vegeterians. 
7.SEASONAL VARIATION 
KAALAM    NO OF CASES       PERCENTAGE(%) 
KAAR KAALAM 
Aug 17 – Oct 17  
- - 
KOOTHIR KAALAM 
 Oct 18 – Dec 15  
- - 
MUNPANI KAALAM 
Dec 16 – Feb 12  
- - 
PINPANI KAALAM 
Feb 13 – Apr 13  
- - 
ELAVENIL KAALAM 
Apr 14 – Jun 16  
- - 
MUTHUVENIL KAALAM 
Jun 17 – Aug 16  
40 100 
Inference:  All the  40 cases (100 %)  were admitted  in muthuvenil kalam. i.e 
between  june 17 to august 16. 
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DIETARY HABITS NO OF CASES PERCENTAGE(%) 
VEGETARIAN 8 20 
NON VEGETARIAN 32 80 
TOTAL 40 100 
8.THINAI 
 
 
 
 
 
 
 
       
Inference: 
Among the 40 cases 31 cases (77.5%) were from Neithal and 9 cases (22.5%) 
were from Marutham  thinai. 
  
  
22.5 % 
77.5 % 
THINAI 
MARUTHAM NEITHAL 
THINAI NO OF CASES PERCENTAGE(%) 
KURINJI  - - 
MULLAI -  
MARUTHAM 9 22.5  
NEITHAL 31 77.5 
PALAI - - 
TOTAL 40 100 
8. SOCIO ECONOMIC STATUS 
CLASS      NO OF CASES  PERCENTAGE(%) 
UPPER CLASS 4 10 
MIDDLE CLASS 26 65 
LOWER CLASS 10 25 
TOTAL 40 100 
 
 
Inference: 
Among the 40 cases, 26 cases (65%) were from middle class ,10 cases (25%) 
were from poor class, 4 cases (10%) were from rich class. 
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9.OCCUPATIONAL STATUS 
 
OCCUPATION      NO OF CASES   PERCENTAGE(%) 
HOME MAKER 23 57.5 
TEACHER 2 5 
WATCH MAN 3 7.5 
TAILOR 2 5 
FARMER 6 15 
POLICE 1 2.5 
DRIVER 3 7.5 
TOTAL 40 100 
 
 
 
Inference:  
Among the 40 patients, 23 patients ( 57.5 % ) were homemakers, 2 
patients(5%) were teacher, 3 patients ( 7.5 % ) were watch man, 2 patients 5 % ) were  
tailor, 6 patients ( 15 % ) were farmer, 1 patient(2.5%) was police, 3 patients (7.5 % ) 
were driver. 
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10.PRECIPITATING FACTOR 
 
 
 
 
 
 
 
 
Inference :  
   Among the 40 patients, 14 patients ( 35 % ) had the history of 
menopause, 20 cases ( 50 % ) had the history of increased house maintenance, 
12cases ( 30 % ) had the history of obesity, 17 cases ( 42.5 % ) had the history of 
occupational related, and 17 patients (42.5) had  age related history. 
  
42.5 % 
30% 
35% 
42.5% 
50% 
PRECIPITATING FACTOR 
Age Factor 
Obesity 
Menopause 
Occupational related  
Increased house 
maintenance 
FACTORS      NO OF CASES     PERCENTAGE(%) 
Age Factor 17 42.5 
Obesity 12 30 
Menopause 22 55 
Occupational related  17 42.5 
Increased house 
maintenance 
20 50 
11.CHRONICITY OF ILLNESS 
 
  CHRONICITY      NO OF CASES   PERCENTAGE(%) 
Up to 3     months 3 7.5 
4 – 12       months  14 35 
13 – 18     months  8 20 
19 – 24     months  6 15 
25 – 30     months 4 10 
Above 30 months 5 12.5 
Total  40 100 
 
 
Inference : 
Among the 40 cases majority of them were 4 – 12 months in their 
duration of illness, i.e, 14 cases(35%) and 8 patients (20%) had 13-18 months 
duration of illness. 
  
0 
5 
10 
15 
20 
25 
30 
35 
7.5 % 
35 % 
20 % 
15 % 
10 % 12.5 % 
   CHRONICITY 
Up to 3     months 4 – 12       months  13 – 18     months  
19 – 24     months  25 – 30     months Above 30 months 
12. CLINICAL FEATURES 
CLINICAL FEAUTURES      NO OF CASES PERCENTAGE(%) 
Pain in knee joints 40 100 
Swelling in knee joints 28 70 
Warmth over the knee joints 12 30 
Tenderness in knee koints 15 37.5 
Morning stiffness of knee joints 13 32.5 
Instability  04 10 
Crepitation of the knee joints 22 55 
Deformity(Genu varum) 01 2.5 
Restricted movements of knee 
joints. 
37 92.5 
 
          
Inference : 
In clinical features,all the 40 cases (100%) had Pain, 13 cases (32.5%) 
had morning stiffness, 22 patients had crepitation(55%), restricted movements in  37 
patients(92.5%) in their affected knee joints. 28 cases ( 70 % ) had swelling, 12 
cases(30%) had warmth, 15 cases ( 37.5 % ) had tenderness, 4 cases (10%) had 
instability and only one  patient had Genu varum deformity. 
13. DISTURBANCES IN KANMENTHIRIYAM 
Kaal was affected in all the 40 cases(100%) due to difficulty in walking. 
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CLINICAL FEATURES 
14.DISTURBANCES IN VATHAM 
 
 
 
 
 
 
 
 
 
 
Inference :  
Out of 40 cases observed ,viyanan and samanan  were affected in all 
the 40 cases(100%) resulted in movements of knee joints , abanan was affected in 4 
cases(10%) resulted constipation,  koorman was affected in 11cases(27.5%) resulted 
in  diminished vision, kirugaran was affected in7 cases,(17.5%)  resulted in loss of  
appetite  and  Devathaththan was affected in 6 (15 %) cases resulted in sleeplessness. 
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VATHAM            NO OF CASES    PERCENTAGE(%) 
Pranan 2 5 
Abanan 4 10 
Uthanan 0 0 
Viyanan 40 100 
Samanan 40 100 
Nagan 0 0 
Koorman  11 27.5 
Kirugaran 7 17.5 
Thevathathan  6 15 
Thananjeyan 0 0 
15.DISTURBANCES IN PITHAM 
PITHAM NO OF CASES PERCENTAGE(%) 
Anarpitham 12 30 
Ranjagapitham 08 20 
Sathagam 40 100 
Prasagam 01 2.5 
Alosagam 11 27.5 
 
 
 
Inferenecs : 
Out of 40 cases, saathaga piththam was affected in almost almost all 
the cases (100%) resulted in walking, anarpitham was affected in 12cases (30%)  
resulted in loss of appetite, alosagam was affected in 11 cases (27.5%) resulted in 
diminished vision, and  Ranjaka piththam was affected in   8 cases (20%) resulted in 
pallor. 
16. DISTURBANCES IN KABAM  
 
Out of 40 cases, santhigam was affected in all the 40 cases (100%) 
resulted in difficulty in movements of knee joints. Avalambagam was affected due to 
santhigam affected. 
  
30% 
20% 
100% 
2.5% 27.5% 
PITHAM 
Anarpitham 
Ranjagapitham 
Sathagam 
Prasagam 
Alosagam 
17.UDALTHATHUKKAL 
THAHTUKKAL NO OF CASES PERCENTAGE 
Saaram 40 100 
Senneer 08 20 
Oon 28 70 
Kozhuppu 40 100 
Enbu 40 100 
Moolai  40 100 
Sukkilam / suronitham  0   0 
 
 
Inference: 
  Among the 7 udal kattugal, Saaram,  Enbu,  kozhuppu and moolai 
were affected in all the 40 cases (100 %) resulted in weakness, pain and morning 
stiffness occurs in affected knee joints. Oon was affected in 28 cases (70%) resulted 
in swelling in affected in knee joints. Senneer was affected in 8 cases (20%)  resulted 
in pallor and reduction in haemoglobin level.  
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18. ENVGAI THERVUGAL 
 
ENVAGAI THERVUGAL NO OF CASES PERCENTAGE 
Naadi (Thontham) 40 100 
Naa (Pallor) 8 20 
Niram (Pallor of skin) 0 0 
Mozhi 0 0 
Vizhi (Pallor) 8 20 
Sparisam (Warmth) 12 30 
 Malam (Constipation) 4 10 
Moothiram 0 0 
 
   
In almost all the cases altered naadi was observed most of them had vaatha 
pitha naadi, Malam was affected in 4cases(10%)  due to constipatipn,  vizhi was 
affected in 8 cases(20%) due to pallor and sparisam was affected in 12 cases(30%) 
due to warmth over the affected knee joints.  
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 19.KOSANGAL 
KOSANGAL NO OF CASES PERCENTAGE 
Annamaya kosam 7      17.5 
Pranamaya koosam 0       0 
Manomaya kosam 14     35 
Vignanamaya 
kosam 
40    100 
Aananthamaya 
kosam 
0       0 
 
 
 
Inference:  
Among the 40 cases , annamaya kosam  was affected in 7 cases(25 %) 
resulted in loss of appetite, manomaya kosam was affected in 14 cases(35 %) resulted 
in depression, and vignanamaya kosam was affected in 40 cases (100 %) resulted in 
pain in knee joints. 
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20.NAADI 
NAADI   NO OF CASES   PERCENTAGE 
Vatha pitham 24 60 
Vatha kabam 6 15 
Pitha vatham  7 17.5 
Pitha kabam 2 5 
Kaba vatham 1 2.5 
Kaba pitham 0 0 
Total 40 100 
 
 
 
Inference :  
  Among the 40 cases vatha  pitha nadi felt in 24 cases ( 60 % ), pitha 
vatha nadi felt in 7 cases ( 17.5 % ), pitha kaba nadi was felt in 2cases(5 %), vatha 
kaba nadi felt  in 6 case ( 15 % ) and kabavatham felt in only one case (2.5%) 
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21. NEIKURI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference:  
Among the 40 cases,in 29cases (72.5 %)  the neikuri was observed as 
kaba neer and 11 cases (27.5 %)  observed as  vaatha neer. 
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NEIKURI     NO  OF CASES PERCENTAGE(%) 
ARAVENA NEENDATHU 
 (vatha neer -lengthening like a snake ) 
11 27.5 
AAZHI POL PARAVIATHU  
( pitha neer – spreading like a ring ) 
0 0 
MUTHTHU POL NINRATHU  
( kaba neer – appears like a pearl ) 
29 72.5 
                         TOTAL 40 100 
X-RAY OF KNEE OSTEOARTHRITIS 
 
  
 
IP NO : 4958 
A/S  : 60 / M 
 
 
 
IP NO :3985 
A/S  : 54 / F 
 
 
 
OP NO : C53913 
A/S  :  52/ F 
 
 
 
 
OP NO : C72639 
A/S  :  45/ M 
  
22. INVOLVEMENT OF KNEE JOINTS 
 
KNEE JOINTS NO OF CASES PERCENTAGE(%) 
Both knee joints                31                    77.5 
 
Right knee joint 
only 
                5                    12.5 
 
Left knee joint only                 4                    10 
 
Total                  40                   100 
 
 
 
Inference : 
      Among the 40 patients,  in 31 cases(77.5%) the disease was affected in    both 
knee joints, in 5 cases(12.5%) it was only in right knee joint only,4 cases(10%)  found 
in left knee joint only. 
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23.OUTCOME MEASUREMENTS 
  PRIMARY OUTCOME 
PAIN SCALE 
   BEFORE TREATMENT     AFTER TREATMENT 
NO OF 
CASES 
PERCENTGAE(%) NO OF 
CASES 
PERCENTGAE(%) 
NO PAIN     [0] 0 0 23 57.5 
MILD PAIN [1-3] 14 35 11 27.5 
MODERATE PAIN [4-6] 19 47.5 6 15 
SEVERE[7-10] 7 17.5 0 0 
 
               
Numeric Rating Scale (0-10) for pain  
  0  No pain 
1-3  Mild pain (Nagging, Annoying, Interfering little with ADLs) 
4-6  Moderate pain (Interferes significantly with ADLs) 
7-10  Severe pain (Disabling, unable to perform ADLs) 
     (ADLs-Activities of daily living) 
Reference –National institute of health, Warren Grant magnuson clinical care, 
pain intensity instruments-july 2003 
Inference:   
Among the 40 cases, after treatment there was no pain in 23 cases 
(57.5%), mild pain in 11 cases (27.5%), and moderate pain in 6 cases(15%). 
  
  SECONDARY OUTCOME 
CLINICAL FEATURES 
BT AT BT (%) 
SYMPTOMS 
REDUCED 
AT 
% 
Pain in knee joints 40 17 100 23 57.5 
Swelling in knee joints 28 7 70 21 52.5 
Warmth over  12 4 30 8 20 
Tenderness in knee joints 15 5 37.5 10 25 
Morning stiffness 13 2 32.5 11 27.5 
Instability 04 1 10 3 7.5 
Crepitations 22 22 55 0 0 
Genu varum Deformity 01 1 2.5 0 0 
Restricted movements  37 10 92.5 27 67.5 
 
         
 
Inference: 
After treatment 23 cases had relieved from pain, 21 cases had relieved 
from swelling, 8 cases had relieved from warmth, 10 cases had relieved from 
tenderness, 11 cases had relieved from morning stiffness, 3 cases had relieved from 
instability, 27 cases had relieved from restricted movements. 
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SECONDARY OUTCOME 
24.RESULTS 
       RESULTS NO OF CASES PERCENTAGE(%) 
Good improvement 23 57.5 
Moderate improvement 11 27.5 
Mild improvement   6 15 
Total  40 100 
 
 
    
 
Inference: 
Out of the  40 cases good improvement was observed in  23 patients (57.5 % ), 
moderate improvement in 11 patients ( 27.5 % ) and  mild improvement in 6 patients 
(15) 
RESULT  FROM TO 
GOOD  1-3 and 4-6 0 
MODERATE 4-6 1-3 
MILD 7-10 4-6 
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PAIN ASSESSMENT SCALE 
  
SL. 
NO 
OP/IP 
NO 
NAME 
 
 
Age/sex 
 PAIN ASSESSMENT SCALE 
Before 
treatment 
After 
treatment 
1. C 80468 Mrs. V.Vijayakumari 55/F 2 0 
2. C 80519 Mrs. C.Kanniyammal 38/F 4 0 
3. C 78091 Mrs. R.Pushpalatha 42/F 3 0 
4. C 73170 Mr. C.Ravikumar 58/M 5 1 
5. C 42985 Mr. G.Sivakumar 43/M 2 0 
6. C 40346 Mrs. V.Kavitha 32/F 1 0 
7. C 53913 Mrs. B.Poongothai 52/F 6 2 
8. C 31928 Mrs. P.Selvi 40/F 4 0 
9. C 66825 Mrs. M.Sudha 45/F 5 0 
10. C 14089 Mrs. M.Krishnaveni 45/F 3 0 
11. C 82185 Mrs. J.Roselin 48/F 6 2 
12. C 61182 Mrs. R.Anjalidevi 39/F 5 1 
13. C 81090 Mrs. A.Visalatchi 36/F 2 0 
14. C 40799 Mrs. I.Girija 44/F 2 0 
15. C 23304 Mrs. G.Manimegalai 53/F 5 1 
16. C 78695 Mrs. D.Mala 54/F 3 0 
17. C 80538 Mrs. S.Tamilmani 58/F 9 6 
18. C 10440 Mrs. K.Bhuvaneswari 40/F 4 0 
19. C 52539 Mrs. K.Banumathi 55/F 7 2 
20. C 73713 Mr. R.Paramasivam 60/M 2 0 
21. C 83683 Mr.B.Shanmugasundaram 48/M 3 0 
22. C 3464 Mrs. C.Rani 60/F 1 0 
23. C 61756 Mrs. B.Suseela 60/F 8 5 
24. C 73565 Mrs. R.Aadhilakshmi 60/F 5 1 
25. B 20623 Mrs. Saraswathi 52/F 4 0 
26. C 81675 Mrs. P.Santhnam 39/F 6 2 
27. C 83165 Mr. S.Muniyan 45/M 5 3 
28. C 85803 Mr. R. Srinivasan 60/M 3 0 
29. C 72639 Mr. P.Senthikumar 45/M 3 0 
30. C 85465 Mr. S.Srinivasan 42/M 6 2 
31. 4878 Mr. M.Kuppusamy 58/M 5 0 
32. 4958 Mr. M.Velusami 60/M 5 2 
33. 4911 Mr. M.Wahab 55/M 9 6 
34. 4953 Mr. C.Santhanam 58/M 4 0 
35. 3958 Mrs. C.Anthoniammal 50/F 9 4 
36. 3985 Mrs. S.Suseela 54/F 8 5 
37. 4019 Mrs. S.Mahalakshmi 47/F 5 0 
38. 4017 Mrs. G.Baby 32/F 3 0 
39. 4046 Mrs.Lakshmi 52/F 4 0 
40. 4078 Mrs. D.Kaliyammal 55/F 9 6 
STATISTICAL ANALYSIS  
All collected data were entered into MS Excel software using different 
columns as variables and rows as patients. SPSS software was used to 
perform statistical analysis. Basic descriptive statistics include frequency 
distributions and cross-tabulations were performed. The quantity 
variables were expressed as Mean ± Standard Deviation and qualitative 
data as percentage. A probability value of <0.05 was considered to 
indicate as statistical significance. Paired ‘t’ test was performed for 
determining the significance between before and after treatment. 
 
 
Mean and Standard deviation of pain score at start, during and end of treatment 
 
 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error 
Mean 
Pair 1 painb 4.63 40 2.238 .354 
paina 1.27 40 1.935 .306 
 
 
Paired Samples Test 
 t df Sig. (2-tailed) 
Pair 1 painb - paina 20.154 39 0.001 
 
The mean± standard deviation of pain score at before and after 
treatment were 4.63 ± 2.24 and 1.27 ± 1.93 respectively which is 
statistically significant (t= 20.154 p<0.001). 
  
Hb and RBC – INVESTIGATIONS BEFORE AND AFTER TREATMENT – IN IP & OP 
PATIENTS 
 
  
SL 
NO 
OP/IP 
NO 
NAME Age/sex 
Hb gm% 
TRBC 
Million cells /cumm 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
1. C 80468 Mrs. V.Vijayakumari 55/F 10.9 11 3.8 5.0 
2. C 80519 Mrs. C.Kanniyammal 38/F 12.7 12.5 4.2 4.3 
3. C 78091 Mrs. R.Pushpalatha 42/F 10.1 12.0 4.4 4.7 
4. C 73170 Mr. C.Ravikumar 58/M 14.8 15.0 5.0 5.1 
5. C 42985 Mr. G.Sivakumar 43/M 15.2 14.8 4.3 4.9 
6. C 40346 Mrs. V.Kavitha 32/F 13.6 14.0 4.9 4.7 
7. C 53913 Mrs. B.Poongothai 52/F 12.8 13.8 4.5 4.6 
8. C 31928 Mrs. P.Selvi 40/F 9.8 15.9 3.9 4.0 
9. C 66825 Mrs. M.Sudha 45/F 13.5 13.5 4.6 5.1 
10. C 14089 Mrs. M.Krishnaveni 45/F 12.1 12.5 5.0 4.9 
11. C 82185 Mrs. J.Roselin 48/F 12.2 13.3 5.1 5.3 
12. C 61182 Mrs. R.Anjalidevi 39/F 10.0 12.5 4.2 4.8 
13. C 81090 Mrs. A.Visalatchi 36/F 12.8 14.9 4.9 4.7 
14. C 40799 Mrs. I.Girija 44/F 9.3 10.0 4.2 4.3 
15. C 23304 Mrs. G.Manimegalai 53/F 8.9 10.5 4.5 4.2 
16. C 78695 Mrs. D.Mala 54/F 11.9 11.0 4.7 4.8 
17. C 80538 Mrs. S.Tamilmani 58/F 10.0 12.6 4.1 4.1 
18. C 10440 Mrs. K.Bhuvaneswari 40/F 14.8 13.5 4.9 4.6 
19. C 52539 Mrs. K.Banumathi 55/F 12.8 16.3 4.1 4.2 
20. C 73713 Mr. R.Paramasivam 60/M 15.5 16.0 5.6 5.1 
21. C 83683 Mr.B.Shanmugasundaram 48/M 15.3 15.8 5.4 5.4 
22. C 3464 Mrs. C.Rani 60/F 12.9 13.0 4.9 5.1 
23. C 61756 Mrs. B.Suseela 60/F 12.7 14.3 5.1 4.9 
24. C 73565 Mrs. R.Aadhilakshmi 60/F 13.3 14.3 5.0 4.9 
25. B 20623 Mrs. Saraswathi 52/F 13.6 15.3 4.5 4.2 
26. C 81675 Mrs. P.Santha 39/F 13.7 14.0 4.6 4.8 
27. C 83165 Mr. S.Muniyan 45/M 16.5 16.1 5.5 4.3 
28. C 85803 Mr. R. Srinivasan 60/M 14.2 15.5 4.6 4.3 
29. C 72639 Mr. P.Senthikumar 45/M 14.5 13.9 4.9 4.8 
30. C 85465 Mr. S.Srinivasan 42/M 15.1 15.2 5.1 5.0 
31. 4878 Mr. M.Kuppusamy 58/M 13.2 13.2 4.6 5.2 
32. 4958 Mr. M.Velusami 60/M 9.5 10.0 3.7 4.0 
33. 4911 Mr. M.Wahab 55/M 15.7 15.2 5.2 4.9 
34. 4953 Mr. C.Santhanam 58/M 12.6 13.0 4.2 3.9 
35. 3958 Mrs. C.Anthoniammal 50/F 16.3 16.1 5.0 4.3 
36. 3985 Mrs. S.Suseela 54/F 14.2 1230 4.6 5.1 
37. 4019 Mrs. S.Mahalakshmi 47/F 13.6 12.7 4.4 4.1 
38. 4017 Mrs. G.Baby 32/F 12.0 13.6 4.4 4.6 
39. 4046 Mrs.Lakshmi 52/F 9.4 11.5 4.1 5.1 
40. 4078 Mrs. D.Kaliyammal 55/F 11.4 11.9 3.9 4.1 
CHOLESTEROL PROFILE OF THE OPD AND IPD PATIENTS (BEFORE AND AFTER TREATMENT) 
 
S. 
NO 
OP/IP 
NO 
Age/se
x 
T.CHOLESTEROL 
mg/dl 
HDL mg/dl LDL mg/dl 
VLDL 
mg/dl 
TGL mg/dl 
BT AT BT AT BT AT BT AT BT AT 
1. C 80468 55/F 231 238 36 38 157 160 38 39 192 196 
2. C 80519 38/F 218 186 64 41 131 119 23 26 117 125 
3. C 78091 42/F 214 193 53 36 123 127 28 30 131 152 
4. C 73170 58/M 230 220 35 36 163 127 55 16 169 159 
5. C 42985 43/M 265 259 49 36 186 186 30 37 153 182 
6. C 40346 32/F 125 193 51 49 127 127 17 17 90 84 
7. C 53913 52/F 245 247 38 39 184 184 23 23 113 117 
8. C 31928 40/F 170 165 40 38 110 107 20 20 161 159 
9. C 66825 45/F 180 178 45 46 115 115 30 29 92 95 
10. C 14089 45/F 116 190 36 38 146 131 14 21 72 105 
11. C 82185 48/F 200 164 42 35 112 125 36 18 189 100 
12. C 61182 39/F 195 190 30 26 142 132 25 25 160 141 
13. C 81090 36/F 154 160 36 40 100 100 19 20 91 93 
14. C 40799 44/F 152 149 36 40 100 102 35 26 111 121 
15. C 23304 53/F 202 205 36 35 156 150 16 20 84 90 
16. C 78695 54/F 171 180 36 45 106 110 29 25 148 150 
17. C 80538 58/F 204 205 30 36 135 137 39 27 158 150 
18. C 10440 40/F 180 175 30 33 132 129 18 16 157 155 
19. C 52539 55/F 235 210 67 45 114 120 54 45 200 180 
20. C 73713 60/M 199 168 40 37 139 112 20 19 100 97 
21. C 83683 48/M 141 118 36 35 18 70 25 13 110 66 
22. C 3464 60/F 241 200 48 50 153 105 40 45 203 180 
23. C 61756 60/F 260 245 38 62 190 157 32 26 162 133 
24. C 73565 60/F 195 190 31 33 142 129 22 20 110 115 
25. B 20623 52/F 169 172 49 50 98 98 22 24 155 155 
26. C 81675 39/F 205 205 42 44 128 121 20 35 165 160 
27. C 83165 45/M 198 200 40 40 122 124 36 36 169 170 
28. C 85803 60/M 210 207 36 44 138 138 26 25 169 135 
29. C 72639 45/M 210 208 48 38 136 159 36 11 116 120 
30. C 85465 42/M 231 238 36 38 157 160 38 39 192 196 
31. 4878 58/M 218 186 64 41 131 119 23 26 117 125 
32. 3958 50/F 214 193 53 36 123 127 28 30 131 152 
33. 4911 55/M 231 200 32 30 153 125 50 45 168 160 
34. 4953 58/M 180 175 30 33 132 129 18 16 157 155 
35. 4958 60/M 235 210 67 45 114 120 54 45 200 180 
36. 3985 54/F 220 225 55 47 112 126 49 44 201 179 
37. 4019 47/F 126 143 26 33 66 65 16 16 80 80 
38. 4017 32/F 145 146 26 33 58 62 17 18 189 182 
39. 4046 52/F 200 198 27 34 56 60 18 24 201 179 
40. 4078 55/F 158 170 35 30 120 079 26 22 153 109 
 
  
Sno OP/IP 
No 
Age/Sex TC 
Cells/ 
cumm 
DC% ESR Blood sugar 
mg/dl 
Blood 
urea 
mg/dl 
S. 
Creat. 
 
S.Uric 
acid 
mg/dl 
ASO CRP RA 
Factor 
P L E M 1/2 hr 1 hr F PP 
1 C80468 55/F 8800 74 23 3 0 10 30 102 120 35 1.0 6.1 - ve - ve - ve 
2 C80519 38/F 6600 55 40 4 1 4 20 100 120 26 0.8 3.7 - ve - ve - ve 
3 C78091 42/F 6500 49 47 4 0 4 10 74 126 22 0.7 4.6 - ve - ve - ve 
4 C73170 58/M 8400 54 41 4 1 2 4 121 135 16 0.5 6.5 - ve - ve - ve 
5 C42985 43/M 8900 69 23 7 1 10 20 102 139 21 0.7 5.8 - ve - ve - ve 
6 C40346 32/F 9500 60 33 6 1 6 16 117 149 18 0.5 5.7 - ve - ve - ve 
7 C53913 52/F 9100 60 12 4 2 8 16 106 128 22 0.7 3.9 - ve - ve - ve 
8 C31928 40/F 9400 60 33 5 2 10 22 101 131 15 0.5 6.9 - ve - ve - ve 
9 C66825 45/F 8400 65 33 2 0 6 14 84 94 23 0.6 6.0 - ve - ve - ve 
10 C14089 45/F 9100 70 24 5 1 2 8 78 108 35 0.9 7.0 - ve - ve - ve 
11 C82185 48/F 6300 70 25 5 0 10 22 92 138 25 0.8 4.6 - ve - ve - ve 
12 C61182 39/F 10400 60 33 7 0 18 38 85 123 26 0.8 4.3 - ve - ve - ve 
13 C81090 36/F 7400 61 36 3 0 2 4 80 105 25 0.5 3.1 - ve - ve - ve 
14 C40799 44/F 6000 60 36 3 1 4 8 106 126 16 0.7 5.7 - ve - ve - ve 
15 C23304 53/F 6900 65 33 2 0 2 4 97 123 26 0.8 7.0 - ve - ve - ve 
16 C78695 54/F 6000 56 39 5 0 2 12 89 131 22 0.7 4.5 - ve - ve - ve 
17 C80538 58/F 6300 60 33 5 2 4 12 99 143 36 0.9 4.7 - ve - ve - ve 
18 C10440 40/F 7700 60 35 5 0 8 22 105 143 16 0.5 3.3 - ve - ve - ve 
19 C52539 55/F 7200 49 43 8 0 4 14 97 117 24 0.7 3.4 - ve - ve - ve 
20 C73713 60/M 6600 59 37 4 3 2 4 90 120 22 0.7 5.6 - ve - ve - ve 
21 C83683 48/M 9300 71 24 4 1 6 14 100 124 21 0.6 6.9 - ve - ve - ve 
22 C 3464 60/F 6200 55 40 5 0 6 14 93 105 30 0.9 4.5 - ve - ve - ve 
23 C61756 60/F 9800 13 23 4 0 20 46 87 123 19 0.6 5.9 - ve - ve - ve 
24 C73565 60/F 7500 69 25 5 1 6 12 99 115 14 0.5 4.5 - ve - ve - ve 
25 B20623 52/F 8200 72 23 5 0 16 36 104 141 32 1.0 4.2 - ve - ve - ve 
26 C81675 39/F 6400 61 33 5 1 6 8 92 105 23 0.8 5.2 - ve - ve - ve 
27 C83165 45/M 8300 60 32 8 0 4 8 80 116 15 0.4 3.6 - ve - ve - ve 
28 C85803 60/M 6400 63 36 1 0 8 16 80 148 21 0.6 5.7 - ve - ve - ve 
29 C72639 45/M 8900 67 28 5 0 8 16 75 85 18 0.5 7.1 - ve - ve - ve 
30 C85465 42/M 8300 70 20 8 2 5 10 101 140 23 0.7 4.2 - ve - ve - ve 
31 4878 58/M 8000 53 43 4 0 10 20 74 101 21 0.6 4.3 - ve - ve - ve 
32 4958 60/M 7800 69 30 1 0 12 24 66 101 19 0.6 4.6 - ve - ve - ve 
33 4911 55/M 10400 50 48 2 0 6 12 92 121 29 0.7 3.0 - ve - ve - ve 
34 4953 58/M 7000 55 43 1 1 6 12 90 98 16 0.6 3.4 - ve - ve - ve 
35 3958 50/F 7800 70 29 1 0 6 12 95 136 26 0.6 6.0 - ve - ve - ve 
36 3985 54/F 6400 50 46 4 0 12 24 74 84 16 0.8 3.5 - ve - ve - ve 
37 4019 47/F 8000 56 40 4 0 2 8 90 120 16 0.5 4.8 - ve - ve - ve 
38 4017 32/F 8600 55 42 3 0 4 8 108 132 42 0.9 4.6 - ve - ve - ve 
39 4046 52/F 11000 60 36 3 2 10 20 93 105 28 0.7 6.1 - ve - ve - ve 
40 4078 55/F 9300 42 39 19 0 4 8 100 117 27 0.7 6.3 - ve - ve - ve 
LAB INVESTIGATIONS  BEFORE TREATMENT 
  
Sno OP/IP   
    No 
Age/Sex   TC  
Cells/ 
cumm 
                   DC%           ESR Blood sugar  
      mg/dl 
Blood 
urea 
mg/dl 
S. 
Creat. 
 
S.Uric  
acid 
 mg/dl 
ASO  CRP RA 
Factor 
    P     L    E  M 1/2 hr 1 hr F PP 
1 C80468 55/F 7100 60 36 2 2 20 40 108 120 16 0.6 2.7 - ve - ve - ve 
2 C80519 38/F 6600 66 36 1 3 10 20 130 105 18 0.5 2.9 - ve - ve - ve 
3 C78091 42/F 8000 57 42 1 0 8 16 77 97 15 0.6 6.5 - ve - ve - ve 
4 C73170 58/M 7900 55 44 1 0 2 4 98 109 15 0.6 4.9 - ve - ve - ve 
5 C42985 43/M 6900 57 39 2 2 4 8 77 99 15 0.6 3.1 - ve - ve - ve 
6 C40346 32/F 7600 66 30 2 2 8 16 104 114 22 0.6 4.3 - ve - ve - ve 
7 C53913 52/F 11400 43 55 2 0 8 16 103 115 27 0.7 4.1 - ve - ve - ve 
8 C31928 40/F 8000 70 26 3 1 14 28 74 86 20 0.6 4.1 - ve - ve - ve 
9 C66825 45/F 6800 68 37 5 0 8 16 100 120 25 0.7 3.7 - ve - ve - ve 
10 C14089 45/F 8400 50 48 2 0 10 20 96 109 25 6 4.8 - ve - ve - ve 
11 C82185 48/F 6900 48 48 2 2 6 12 100 110 35 0.8 4.6 - ve - ve - ve 
12 C61182 39/F 6500 50 45 3 2 6 12 97 110 25 0.8 5 - ve - ve - ve 
13 C81090 36/F 9800 62 32 4 2 6 12 100 140 27 0.8 3.6 - ve - ve - ve 
14 C40799 44/F 9500 50 45 3 2 6 12 108 135 30 0.8 4.5 - ve - ve - ve 
15 C23304 53/F 8400 59 36 4 1 6 12 100 120 45 1 5 - ve - ve - ve 
16 C78695 54/F 8000 60 38 2 0 3 6 110 120 28 0.7 3.5 - ve - ve - ve 
17 C80538 58/F 8000 64 34 2 0 3 6 100 110 30 0.8 5 - ve - ve - ve 
18 C10440 40/F 7000 52 45 2 1 4 8 110 140 15 0.6 6.5 - ve - ve - ve 
19 C52539 55/F 7900 58 40 2 0 4 8 85 95 18 0.6 3.1 - ve - ve - ve 
20 C73713 60/M 5500 15 42 5 3 6 12 106 115 15 0.6 3.8 - ve - ve - ve 
21 C83683 48/M 7500 17 28 3 1 8 16 106 132 17 0.8 4 - ve - ve - ve 
22 C 3464 60/F 7600 48 37 2 3 8 16 94 106 31 0.8 3.4 - ve - ve - ve 
23 C61756 60/F 8500 62 30 8 0 6 12 66 101 17 0.6 3.2 - ve - ve - ve 
24 C73565 60/F 7900 54 45 1 0 8 16 85 104 16 0.6 4.1 - ve - ve - ve 
25 B20623 52/F 7200 60 45 3 2 6 12 95 110 18 0.8 3.6 - ve - ve - ve 
26 C81675 39/F 7800 70 28 1 1 6 12 80 130 28 0.7 4.1 - ve - ve - ve 
27 C83165 45/M 6400 58 38 2 2 8 16 90 120 20 0.6 3.5 - ve - ve - ve 
28 C85803 60/M 9400 65 33 2 0 6 12 110 120 50 0.6 2.6 - ve - ve - ve 
29 C72639 45/M 8200 58 37 5 0 14 28 104 135 16 0.6 4.6 - ve - ve - ve 
30 C85465 42/M 7500 60 40 4 2 7 14 105 120 30 0.9 4.2 - ve - ve - ve 
31 4878 58/M 7800 70 28 1 1 6 12 80 130 28 0.7 4.1 -ve - ve - ve 
32 4958 60/M 6400 58 38 2 2 8 16 90 120 20 0.6 3.5 - ve - ve - ve 
33 4911 55/M 9400 65 33 2 0 6 12 110 120 50 0.6 2.6 - ve - ve - ve 
34 4953 58/M 8200 58 37 5 0 14 28 104 135 16 0.6 4.6 - ve - ve - ve 
35 3958 50/F 7500 60 40 4 2 7 14 105 120 30 0.9 4.2 - ve - ve - ve 
36 3985 54/F 6200 52 39 6 3 8 16 90 110 0.7 21 0.7 - ve - ve - ve 
37 4019 47/F 7600 55 39 5 1 4 16 88 106 15 0.4 3.6 - ve - ve - ve 
38 4017 32/F 4100 69 30 1 0 8 16 108 125 22 0.6 5.1 - ve - ve - ve 
39 4046 52/F 7200 62 34 3 1 8 16 82 100 23 0.7 5.3 - ve - ve - ve 
40 4078 55/F 8200 60 20 20 0 6 8 104 121 17 0.6 5.9 - ve - ve - ve 
LAB INVESTIGATIONS  AFETR  TREATMENT 
Sno OP/IP 
No 
Age/Sex Total 
Billirubin 
mg/dl 
Direct. 
Billirubin 
mg/dl 
ID. 
Billirubin 
mg/dl 
SGOT 
IU/l 
SGPT 
U/l 
SAP 
U/l 
T.Protein 
gm/dl 
Albumin 
gm/dl 
Globulin 
gm/dl 
Calcium 
mg/dl 
Phosphorous 
mg/dl 
1 C80468 55/F 0.6 0.2 0.4 10 12 345 7.1 5.0 2.1 8.3 3.0 
2 C80519 38/F 0.9 0.3 0.6 10 12 211 6.7 4.1 2.6 9.3 3.2 
3 C78091 42/F 0.6 0.2 0.4 11 13 138 6.7 3.2 3.5 11.0 2.6 
4 C73170 58/M 0.7 0.2 0.5 20 21 143 6.7 4.8 1.9 10.2 3.4 
5 C42985 43/M 1.3 0.5 0.8 32 35 223 6.4 3.7 2.7 2.7 4.0 
6 C40346 32/F 0.6 0.2 0.4 36 44 229 6.6 4.9 1.7 10.3 5.7 
7 C53913 52/F 0.7 0.3 0.4 17 19 189 6.3 4.9 1.4 11.2 3.8 
8 C31928 40/F 0.4 0.2 0.2 08 10 178 6.6 4.8 1.8 10.5 6.9 
9 C66825 45/F 0.6 0.2 0.4 18 20 199 6.9 4.9 2.0 11.0 3.5 
10 C14089 45/F 0.8 0.3 0.5 15 18 188 6.6 4.5 2.1 10.3 3.9 
11 C82185 48/F 0.6 0.2 0.4 20 28 198 6.9 3.2 3.7 9.5 2.5 
12 C61182 39/F 0.6 0.2 0.4 20 21 194 7.0 3.4 3.6 11.5 3.3 
13 C81090 36/F 0.6 0.2 0.4 16 19 197 7.0 5.1 3.1 11.0 3.1 
14 C40799 44/F 0.7 0.2 0.2 12 14 168 7.0 4.9 2.1 11.0 3.6 
15 C23304 53/F 0.5 0.2 0.3 24 25 186 6.5 5.0 1.5 10.0 3.2 
16 C78695 54/F 0.5 0.2 0.3 32 36 158 6.8 3.8 3.0 10.1 3.2 
17 C80538 58/F 0.8 0.3 0.5 27 28 290 7.0 5.0 2.0 11.0 4.7 
18 C10440 40/F 0.4 0.2 0.2 17 18 176 5.8 3.8 2.0 10.0 3.6 
19 C52539 55/F 0.4 0.2 0.2 16 17 156 7.1 5.0 2.1 10.3 3.0 
20 C73713 60/M 0.7 0.4 0.3 20 23 137 6.8 4.7 3.9 9.8 4.0 
21 C83683 48/M 0.5 0.2 0.3 27 29 158 6.6 3.9 2.7 10.0 3.0 
22 C 3464 60/F 0.8 0.3 0.5 21 22 162 6.0 4.0 2.0 11.0 3.6 
23 C61756 60/F 0.6 0.2 0.4 20 21 213 6.5 4.0 2.5 11.4 3.6 
24 C73565 60/F 0.5 0.3 0.2 19 20 139 6.5 4.1 2.4 10.0 2.9 
25 B20623 52/F 0.5 0.2 0.3 28 29 166 5.0 3.0 2.0 11.0 3.6 
26 C81675 39/F 0.4 0.2 0.2 19 20 180 7.1 4.0 3.1 9.9 3.0 
27 C83165 45/M 0.4 0.2 0.2 26 39 291 6.9 3.9 3.0 9.8 3.0 
28 C85803 60/M 0.6 0.3 0.3 16 17 155 7.0 4.0 3.0 10.6 3.1 
29 C72639 45/M 0.6 0.3 0.3 14 15 199 7.0 5.0 2.0 10.1 2.9 
30 C85465 42/M 0.7 0.3 0.4 20 21 166 6.4 4.0 2.4 10.3 3.0 
31 4878 58/M 0.4 0.3 0.1 21 18 140 8.0 4.1 3.9 10.6 4.5 
32 4958 60/M 0.9 0.5 0.4 17 15 204 6.6 3.7 2.9 10.1 3.3 
33 4911 55/M 0.6 0.3 0.3 29 27 156 6.7 3.9 2.8 9.3 4 
34 4953 58/M 0.5 0.3 0.2 19 16 196 7.0 3.9 3.1 10.1 3.6 
35 3958 50/F 0.5 0.2 0.3 35 20 210 6.5 4.6 1.9 9 3.4 
36 3985 54/F 0.7 0.4 0.3 25 19 235 8.3 5.3 3 10.6 8.3 
37 4019 47/F 0.5 0.2 0.3 25 26 170 6.8 4.2 2.6 10.1 3.2 
38 4017 32/F 0.5 0.3 0.2 21 19 296 8.3 4.3 4 8.3 3.7 
39 4046 52/F 0.7 0.4 0.3 21 19 269 6.7 3.6 3.1 8.8 3.4 
40 4078 55/F 0.4 0.2 0.2 26 28 176 6.6 4.1 2.5 10.0 3.0 
LAB INVESTIGATIONS BEFORE TREATMENT 
   
Sno OP/IP 
No 
Age/Sex Total 
Billirubin 
mg/dl 
Direct. 
Billirubin 
mg/dl 
ID. 
Billirubin 
mg/dl 
SGOT 
IU/l 
SGPT 
U/l 
SAP 
U/l 
T.Protein 
gm/dl 
Albumin 
gm/dl 
Globulin 
gm/dl 
Calcium 
mg/dl 
Phosphorous 
mg/dl 
1 C80468 55/F 0.4 0.2 0.2 46 33 171 8.5 4.5 4 10.8 3.3 
2 C80519 38/F 0.6 0.3 0.3 23 30 178 8 4.4 3.6 9.5 3.2 
3 C78091 42/F 0.7 0.4 0.3 22 20 190 7.7 4.1 3.6 10 4 
4 C73170 58/M 0.9 0.5 0.4 18 20 156 11.5 4.5 3 7.8 4.2 
5 C42985 43/M 0.9 0.6 0.3 33 20 182 8 4.3 3.7 9.2 4 
6 C40346 32/F 0.8 0.5 0.3 28 29 180 7.9 4.5 3.4 9 4.2 
7 C53913 52/F 0.8 0.5 0.3 34 36 170 7.2 4.7 2.5 10.6 3.5 
8 C31928 40/F 0.6 0.4 0.2 25 26 253 8 5.1 2.9 8.6 4.1 
9 C66825 45/F 0.6 0.3 0.3 23 16 179 7.6 4 3.6 8 4.5 
10 C14089 45/F 0.5 0.4 0.1 15 22 138 7.2 4.1 3.1 9.1 4.3 
11 C82185 48/F 0.7 0.5 0.2 15 20 203 8.1 5 3.1 9.1 3.4 
12 C61182 39/F 0.6 0.3 0.3 21 17 194 7 4.9 2.1 9.6 4.2 
13 C81090 36/F 0.6 0.3 0.3 22 19 153 8.1 4.1 4 9.7 4.3 
14 C40799 44/F 0.6 0.3 0.3 27 30 184 7.8 4.1 3.7 8.1 3.8 
15 C23304 53/F 0.7 0.5 0.2 29 25 190 7 3.5 3.5 8.2 4.1 
16 C78695 54/F 0.5 0.3 0.2 13 17 169 7.9 4 3.9 10.1 4.5 
17 C80538 58/F 0.5 0.3 0.2 15 21 186 6.9 3.5 3.4 9.6 3 
18 C10440 40/F 0.5 0.3 0.2 19 23 227 8 4.5 3.5 9.6 4.5 
19 C52539 55/F 0.6 0.3 0.3 32 27 280 7 5 2 10.6 5.7 
20 C73713 60/M 0.8 0.5 0.3 39 35 170 7.6 3.9 3.7 9.6 3.3 
21 C83683 48/M 0.7 0.4 0.3 20 18 210 7.9 4.1 3.8 10 4.2 
22 C 3464 60/F 0.8 0.5 0.3 40 34 189 8 4.3 3.7 9.5 4 
23 C61756 60/F 0.6 0.4 0.2 25 20 165 7.8 4.6 3.2 10.4 3.9 
24 C73565 60/F 0.7 0.4 0.3 24 26 215 7.8 4.2 3.6 10.3 3.5 
25 B20623 52/F 0.5 0.3 0.2 20 22 147 8.2 5.6 2.6 9.3 3.6 
26 C81675 39/F 0.6 0.4 0.2 28 25 280 7.6 4.8 2.8 9.6 3.8 
27 C83165 45/M 1 0.5 0.5 30 29 200 7.6 3.8 3.8 9.6 3.6 
28 C85803 60/M 0.8 0.4 0.4 21 18 144 6.9 3.7 3.2 9.6 3.5 
29 C72639 45/M 0.7 0.4 0.3 20 14 206 6.8 5.3 1.5 10.3 3.7 
30 C85465 42/M 0.7 0.5 0.2 20 25 180 8 5 3 9 4.4 
31 4878 58/M 0.6 0.3 0.3 21 13 295 3.3 4.9 3.4 9.6 4.2 
32 4958 60/M 0.7 0.4 0.3 20 19 172 6.3 4.3 2 9.6 4.6 
33 4911 55/M 0.6 0.3 0.3 34 30 236 6.7 4.7 2 9.3 3.3 
34 4953 58/M 0.7 0.4 0.3 26 18 190 7 3.9 3.1 10 3.8 
35 3958 50/F 0.8 0.5 0.3 32 28 250 7 3.8 3.2 9.2 3.4 
36 3985 54/F 0.8 0.5 0.3 27 20 235 8 5 3 10.4 3.3 
37 4019 47/F 0.5 0.2 0.3 17 19 159 5.9 3.6 2.3 10.8 2.9 
38 4017 32/F 0.7 0.5 0.2 27 25 280 6.2 4.7 2.5 10.3 4.7 
39 4046 52/F 0.7 0.4 0.3 23 20 272 6.7 3.6 3.1 9 3.6 
40 4078 55/F 0.6 0.3 0.4 10 12 216 6.9 3.5 3.4 10.4 3.0 
LAB INVESTIGATIONS AFTER TREATMENT 
S. 
NO 
OP/IP 
NO 
URINE MOTION 
Before Treatment After Treatment Before Treatment After Treatment 
Alb Sug 
Deposits BS BP 
Alb Sug 
Deposits BS BP 
Ova Cyst 
Occult 
bld 
Ova Cyst 
Occult 
blood Pus 
Cells 
Epi. 
cells 
Pus cells Epi. cells 
1. C80468 NIL NIL 2-4 1-3 NIL NIL NIL NIL 2-5 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
2. C80519 NIL NIL 4-5 2-3 NIL NIL NIL NIL 1-3 1-3 NIL NIL NIL NIL NIL NIL NIL NIL 
3. C78091 NIL NIL 2-4 2-5 NIL NIL NIL NIL 2-4 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
4. C73170 NIL NIL 2-3 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
5. C42985 NIL NIL NIL NIL NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
6. C40346 NIL NIL 4-5  4-5 NIL NIL NIL NIL 0-4 1-5 NIL NIL NIL NIL NIL NIL NIL NIL 
7. C53913 NIL NIL 2-3 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
8. C31928 NIL NIL 1-2 1-2 NIL NIL NIL NIL 0-1 0-4 NIL NIL NIL NIL NIL NIL NIL NIL 
9. C66825 NIL NIL 2-4 1-2 NIL NIL NIL NIL 1-2 1-4 NIL NIL NIL NIL NIL NIL NIL NIL 
10. C14089 NIL NIL 4-5 1-2 NIL NIL NIL NIL 1-4 1-3 NIL NIL NIL NIL NIL NIL NIL NIL 
11. C82185 NIL NIL 1-2 1-2 NIL NIL NIL NIL 0-1 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
12. C61182 NIL NIL 2-3 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
13. C81090 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
14. C40799 NIL NIL 1-4 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
15. C23304 NIL NIL 2-4 1-3 NIL NIL NIL NIL 2-4 1-3 NIL NIL NIL NIL NIL NIL NIL NIL 
16. C78695 NIL NIL 1-2 1-2 NIL NIL NIL NIL 0-1 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
17. C80538 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
18. C10440 NIL NIL   12 2-4 NIL NIL NIL NIL 0-1 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
19. C52539 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
20. C73713 NIL NIL 1-2 1-2 NIL NIL NIL NIL 2-4 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
URINE AND MOTION INVESTIGATIONS 
S. 
NO 
OP/IP 
NO 
URINE MOTION 
Before Treatment After Treatment Before Treatment After Treatment 
Alb Sug 
Deposits BS BP Alb
umi
n 
Sug
ar 
Deposits BS BP 
Ova Cyst 
Occult 
bld 
Ova Cyst 
Occult 
blood Pus 
Cells 
Epi. 
Cells 
Pus 
Cells 
Epi. 
Cells 
21. C83683 NIL NIL 1-2 1-2 NIL NIL NIL NIL 2-4 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
22. C 3464 NIL NIL 3-5 2-4 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
23. C61756 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
24. C73565 NIL NIL 2-3 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
25. B20623 NIL NIL NIL NIL NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
26. C81675 NIL NIL   4-5   4-5 NIL NIL NIL NIL 1-3 1-5 NIL NIL NIL NIL NIL NIL NIL NIL 
27. C83165 NIL NIL 2-3 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
28. C85803 NIL NIL 1-2 2-4 NIL NIL NIL NIL 0-1 0-4 NIL NIL NIL NIL NIL NIL NIL NIL 
29. C72639 NIL NIL 2-4 4-5 NIL NIL NIL NIL 1-2 1-5 NIL NIL NIL NIL NIL NIL NIL NIL 
30. C85465 NIL NIL 4-5 4-5 NIL NIL NIL NIL 1-4 4-5 NIL NIL NIL NIL NIL NIL NIL NIL 
31. 4878 NIL NIL 1-2 1-2 NIL NIL NIL NIL 0-1 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
32. 4958 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
33. 4911 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
34. 4953 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
35. 3958 NIL NIL 2-4 2-4 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
36. 3985 NIL NIL 2-4 2-4 NIL NIL NIL NIL 0-1 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
37. 4019 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
38. 4017 NIL NIL   1-2 1-3 NIL NIL NIL NIL 0-1 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
39. 4046 NIL NIL 1-2 1-2 NIL NIL NIL NIL 1-2 0-1 NIL NIL NIL NIL NIL NIL NIL NIL 
40. 4078 NIL NIL 1-2 1-2 NIL NIL NIL NIL 2-4 1-2 NIL NIL NIL NIL NIL NIL NIL NIL 
URINE AND MOTION INVESTIGATIONS 
  
 
          
 
 
 
        Discussion 
DISCUSSION 
Azhal keel vayu is a disease characterized by pain and swelling in knee 
joints, morning     stiffness, tenderness, crepitations, restricted movements and low 
grade fever. The signs and symptoms of Azhal keel vayu as per Sapabathy 
kaiyedu and siddha maruthuvam pothu can be correlated with Osteoarthritis in 
Modern science. 
 The aim of the study is to evaluate the therapeutic efficacy of sarva noi linga 
chenduram (internal) and Maasha thylum (external) in the treatment of Azhal 
keel vayu. 
 The protocol has been approved by Institutional Animal Ethical committee 
(IAEC) and Institutional Ethical committee.(IEC) in NIS,Chennai 
IEC/NIS/2011/3/03 
 The required raw drugs for preparation of Sarva noi  linga chenduram and 
Maasha thylum were authenticated by Asst.Prof of Medicinal Botany National 
Institute of Siddha. The drugs were purified and medicine was prepared in 
Gunapadam laboratory of National institute of siddha. 
 The biochemical (both Qualitative and Quantitative analysis) and toxicological 
studies of the trial drug   Sarva noi  linga chenduram were doneNIS and  IIT, 
Chennai. 
 Toxicological studies of the trial drug Sarva noi  linga chenduram was done in 
the of pharmacology lab , National Institute of Siddha and the results were 
documented. 
 The present clinical study was done as per the approved protocol and the data 
were collected by using the prescribed proforma from the 40 cases who were 
treated in the   inpatient ward and outpatient department of Maruthuvam.  
 The patients were treated for a period of 48 days with Sarva noi linga 
chenduram (internal medicine) at the dose of 130 mg, twice a day with the 
adjuvant of honey and Maasha thylum (external medicine) for external 
application.      
Clinical assessment was done during each visit in OPD patients (12 days once) and  
 
daily for IPD patients and the data were noted in the prescribed proforma 
  
The observations discussed below: 
Gender distribution: 
    The majority affected sex was female i.e, 28 cases (70%). The 
common cause for this may be depletion of calcium from their body due to 
menopause and increased house hold works. 
Age distribution: 
  This study showed that the highest incidence of Azhal keel vaayu was 
between    50 – 60 years of age, i.e 23 cases (57.5%), and  40-50 years of age 11 cases 
(27.5%) because degeneration starts from this age. 
Gunam: 
  All the 40 cases under this analysis were predominantly of Rajo gunam 
assessed from interrogation and other observations. 
Kaalam distribution: 
  Among the  40 cases, 38 cases(95%) were found to be in pitha kaalam  
(34-66 yrs) and  only 2 cases ( 5%) were found in the  vaatha kaalam. 
Diet: 
  Among the 40 cases 32 cases (80%) were non-vegetarians.  Non 
vegetarian diet may be the cause for accumulation of fat and there by promoting 
obesity. This altered the weight transferring mechanism in knee joints, causing this 
disease. 
Thinai distribution; 
 In this study, 77.5% of cases were reported from Neithal land.  
  In Siddha literatures, it was mentioned that Neithal is a land, which is 
responsible for vaatha diseases. This study also emphasized the same. 
Socio  Economic Occupational references: 
  Home maker accounts for the highest number of 23 cases (57.5%).  
More weight bearing, improper positioning of knee also produces the impact.  
  
Precipitating factors: 
  Already it was explained that aging is the most common cause for 
Azhal keel vaayu. Apart from that, menopause (55%), increased household works 
(50%), Obesity (30%), occupational related (42.5%) are the precipitating factors. 
Clinical features: 
  Pain in the knee joint present in the 40 cases, morning stiffness were 
present in the 13 cases(32.5%) crepitation in the 22 cases(55%),  and restricted 
movements were present in almost all the 37 cases (92.5%). Swelling was present in 
28 cases (70%), 15 cases (37.5%) had tenderness, 12 cases (30%) had warmth and 
only one  cases had Genuvarum deformity in affected knee joints.  
Kanmenthiriyam: 
  Kaal was affected in all the 40 cases (100%) due to difficulty in 
walking. 23 cases (57.5%) were improved after the treatment. 
Derangements noted in vatham: 
  In all the 40 cases observed ,viyanan and samanan  were 
affected in all the 40 cases(100%) due to difficulty in movements of knee joints , 
abanan was affected in 4 cases(10%) due to constipation,  koorman was affected in 
11cases(27.5%) due to diminished vision owing to age,  kirugaran was affected in7 
cases,(17.5%)  due to  loss of appetite  and  thevathaththan was affected in 6 (15 %) 
cases due to sleeplessness. 
Derangement noted in pitham: 
Out of 40 cases, saathaga piththam was affected in almost almost all 
the cases (100%) due to difficulty in walking, anarpitham was affected in 12cases 
(30%)  due to loss of appetite, alosagam was affected in 19 cases (47.5%) due to  
diminished vision owing to age  and  Ranjaka piththam was affected in   8 cases 
(20%) due to pallor.  
4 cases were improved from their previous haemoglobin level after the 
treatment. 
  
Derangement of kabam: 
  Santhigam was affected in all the 40 cases. Santhiga kabam mainly 
lives in joints and so it was affected in all the cases. 34 cases were improved from 
their walking difficulty after the treatment. 
Udal thathukkal: 
            Among the 7 udal kattugal, Saaram,  Enbu,  kozhuppu and moolai 
were affected in all the 40 cases (100 %) due to weakness, pain and morning stiffness 
occurs in affected knee joints. Oon was affected in 28 cases (70%) due to swelling in 
affected in knee joints. Senneer was affected in 8 cases (20%)  due to pallor and 
reduction in haemoglobin level. 
  40 cases were improved from their pain, 11 cases (27.5%) were 
improved from their morning stiffness, 21cases improved from swelling  (52.5%) 
after the treatment. 
Ennvagai thervugal: 
 Almost all cases affected were examined by the Ennvagai thervugal 
observations. 
Pulse reading (Naadi) was observed in all patients. 24 cases(60%) had 
Vathapitham, 7 cases (17.5%) had Pithavatham,  2 cases had Pithakabam and 6 case 
had vatha kabam. Malam was affected in 4 cases(10%) due to constipation and vizhi 
was affected in 8 cases(20%) due to   pallor, sparisam was affected in 12 cases(30%) 
due to warmth over the affected knee joints 
Derangement of Kosangal 
Among the 40 cases , annamaya kosam  was affected in 7 cases(25 %) 
resulted in loss of appetite, manomaya kosam was affected in 14 cases(35 %) resulted 
in depression, and vignanamaya kosam was affected in 40 cases (100 %) resulted in 
pain in knee joints. 
Neikkuri: 
In 11 cases (27.5) oil was lengthening like a snake i.e, Aravena 
neendathu which indicates vaatha neer and in 29 cases (72.5%) it appeared like a 
pearl i.e, Muthu pol nindrathu which indicates kabaneer. 
Laboratory investigations: 
  Laboratory investigation of blood, urine, stools and  x-ray were done 
for all 40 cases. In laboratory investigations anaemia was found in 6 cases. ESR was 
found raised during study enrollment  and  after treatment it was found reduced. There 
were remarkable changes in  ESR, TRBC and Haemoglobin.   
Blood Urea, serum Creatinine levels have not shown much remarkable changes. 
Radiological investigation 
 The radiographic studies showed narrowed joint space and presence of 
Osteophytes in all 40 cases(100%). No radiographic changes observed after treatment. 
Outcome : 
Primary out come. 
Nature of pain- Pain assessment scale 
 Before treatment mild pain was present in 14(35%) cases, moderate pain  was 
present  in 19(47.5%) cases, and severe pain was present in  7 (17.5%) cases. 
 
 After treatment with the trial medicine Sarva noi linga chenduram(Int)  and 
Maasha thylum(External) for 48 days, no pain was present in  23 cases 
(57.5%) mild pain was  present in 6(15%)  cases, moderate pain was present  
in 7(17.5%) cases. 
 
On the basis of effect of the trial drugs, Good improvement was assessed in 23 
cases(57.5%), moderate improvement in 11 cases(27.5%) and mild improvement in 6 
cases(15%). 
  
Secondary outcome: 
Clinical features:      
 Among the 40 cases, all the 40 cases (100%) had Pain, 13 
cases932.5%) had morning stiffness, 22 patients had crepitation(55%), restricted 
movements in  37 patients(92.5%) in their affected knee joints. 28 cases ( 70 % ) had 
swelling, 12 cases(30%) had warmth, 15 cases ( 37.5 % ) had tenderness, 4 cases 
(10%) had instability and only one  patient had Genu varum deformity. During each 
visit the clinical symptoms were assessed and observations were recorded in the 
prescribed proforma. 
  After treatment with the trial medicine Sarva noi linga 
chenduram, (Internal)&Maasha  thylum (external) for 48 days, 23 cases had relieved 
from pain, 21 cases had relieved from swelling, 8 cases had relieved from warmth, 10 
cases had relieved from tenderness, 11 cases had relieved from morning stiffness, 3 
cases had relieved from instability, 27 cases had relieved from restricted movements. 
Biochemical analysis: 
   
Qualitative analysis of  Sarva noi  linga chenduram reveals that the trial 
medicine  contains the following elements.  
 
 Calcium 
 phosphate 
 Carbonate 
 Iron 
 Aluminium 
 Magnesium 
 Mercury 
 Silicate 
 Sodium 
 Unsaturated Compunds 
TOXICITY STUDIES 
 Acute oral toxicity study: [WHO guidelines, 1993] 
 
Sarva noi linga chenduram  at the dose of  4.68mg/kg/bw  did not exhibit any 
mortality in mice. In Necropsy ,the organs of the animal such as, Liver, Heart, Lungs, 
pancreas Spleen, Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared 
normal. 
 
 Sub acute toxicity study:  [WHO guidelines, 1993] 
 
Sarva noi  linga chenduram at the dose of  23.4/kg/bw(10x) did not exhibit any  
mortality in rats. Biochemical parameters and histopathology report were also normal. 
There were no signs of toxicity. 
 
 
 
 
 
  
  
 
 
                      
 
 
                                
 
       SUMMARY  
  
SUMMARY 
 The aim of the study was to evaluate the efficacy of the drug SARVA NOI 
LINGA CHENDURAM (Internal) and MAASHA THYLAM (External) in 
AZHAL KEEL VAYU 
 Before initiating the clinical trial, approval was got from the Institutional 
Animal Ethical Committee and Institutional Ethical Committee for conducting 
the pre clinical studies and clinical studies respectively by submitting the well 
defined protocol and proforma. 
 The raw drugs were authenticated by the concerned department and the trial 
drug was prepared by the investigator in the Gunapadam lab of National 
Institute of Siddha as per the Standard Operating Procedure mentioned in the 
protocol. 
 The medicine was then subjected to pre clinical  studies (Acute and sub acutr 
toxicity studies) as per the protocol and the safety of the drug was ensured. 
 The qualitative and quantitative bio chemical studies were done at the bio 
chemistry lab of National Institute of Siddha and IIT Chennai respectively. 
 Among the 60 cases screened at the OPD of department of Maruthuvam NIS, 
40 cases were recruited for the trial as per the inclusion and exclusion criteria. 
 Clinical diagnosis of Azhal keel vayu was made by Siddha and Modern 
methodology. 
 Before inducement into the trial informed consent was obtained from the 
patients. Out of the 40 cases  30 cases were treated in OPD and 10 cases in 
IPD. 
 A day before the trial drug administration, puragative medicine   was given  
Agasthiyar kuzhambu 130mg  given to correct the elevated Vatha thathu and 
bring’s other the two deranged thathus to equilibrium. 
 The trial medicines selected for both Internal and External treatment were 
SARVA NOI LINGA CHENDURAM 130 mg b.i.d  with the adjuvant honey 
and MAASHA THYLUM referred under Siddha literature Anupoga Vaithiya 
Navaneetham IV part respectively. 
 During the treatment period of 48 days the trial drug SARVA NOI LINGA 
CHENDURAM (Internal)  is given for 7 days followed by a break (re 
dieting) of 5 days. Likewise the medicine is given till the end of the course 
as given in Siddha Literature. 
 Every first day of the break (re dieting) started with head bath with the 
paste of Ajowan seeds with cow’s milk as indicated in Siddha text.  
 Diet restriction was strictly followed during the period of drug administration 
as well as re dieting period (Diet free of salt, tamarind etc) as per noted in the 
form IV E (Dietary advice form).  
 Required lab investigations were carried out before and after the treatment and 
the concerned data was recorded in the proforma.  
 Clinical assessment was done daily in all the IP patients and in OP patients it 
was assessed once in 12 days. 
 The study Results showed that 57.5 % had good improvement 22.5 % had 
moderate improvement 15 % had mild improvement. 
 As per the Siddha Literature and modern science reviews and research articles, 
the ingredients of the trial drugs were found to have the property of controlling 
the Vatha diseases, some drugs exhibited anti inflammatory and analgesic 
action owing to the disease manifestations. 
 During the study period, there was no event of any adverse reactions owing to 
the drug or disease. 
 Radiological investigation (X ray knee joint- AP & LAT  VIEW) was also 
done before and after treatment. 
 Statistical analysis showed significant reduction in pain scale before and after 
the treatment. ( P <0.001)  Statistical analysis on lab parameters also showed 
significant outcome. 
 Oral toxicity studies conducted ensured the safety usage of the drug to animals 
up to a maximum dose of 23.4 mg/animal. 
 Bio chemical analysis showed the presence of constituents like Calcium, Iron, 
Sulphur which played a role in repairing and preventing the joint damage in 
the disease. The minimum particle size (3 µ) unveiled in the (Particle Per 
Million size) PPM analysis shows the existence of the drug in micro particle 
size which contributes its therapeutic effect by the increased bio availability. 
 
  
  
 
 
 
 
 
 
 
 
    CONCLUSION 
                                     CONCLUSION 
AIM 
The principal aim of the present study is 
 To evaluate the therapeutic efficacy of the Siddha formulations Sarva noi linga 
Chenduram (Internal) and Maasha thylam (External) in the treatment of Azhal 
keel vayu (Osteo arthritis). 
OBJECTIVES 
PRIMARY OBJECTIVE 
 To evaluate the therapeutic efficacy of the Siddha drugs sarva noi linga Chenduram 
(Internal) and Maasha thylum (External) in reducing the pain in Azhal keel vayu (Osteo  
arthritis). 
SECONDARY OBJECTIVE 
 To conduct a clinical trial with a well defined proforma on the patients identified 
with “Azhal keel  vayu ”. 
 To evaluate the safety of the test drugs (Acute and Sub acute toxicity studies) to be 
carried out as per WHO guidelines. 
 To study the influence of other co factors such as age, sex, dietary habits, family history, 
socio economic status, habitat etc on the disease. 
 To study Azhal keel vayu on the basis of  
            (a) Mukkutram                   (b) Udalkattugal                  (c) Envagai thervugal etc         
 To find out the side effects / adverse effects of the drug “SARVA NOI LINGA 
CHENDURAM (Internal) and MAASHA THYLUM (External)” if any. 
 To screen the biochemical constituents of the drug. 
  
  Toxicity study reveals that the trial drug is safe in acute and sub acute  toxicitiy  
even in higher dosage of 46.8 mg/ animal  in albino rats as per WHO guideliness 
1993. 
 Clinical results showed  to be Good improvement in 57.5% of cases, moderate 
improvement in 15% cases and mild improvement in 27.5% of cases. 
 There is significant difference between pain assessment scale of before and after 
treatment ( P <0.001) 
 During the course of the treatment adverse drug reactions were not found. 
 The results of the clinical trail indicates that the trail drugs are clinically 
effective, safe and also economical. 
 Because of the encouraging clinical and laboratory results, the study may be 
extended with the same drug in more number of cases, in treating Azhal keel 
vayu successfully. 
 
  
            
 
 
 
 
 
           
 
       ANNEXURE     I 
        Toxicological                   
               studies 
  
ACUTE TOXICITY STUDY OF SARVA NOI LINGA  CHENDURAM  
[WHO guidelines, 1993] 
Principle: 
Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound. The study duration 
was 14 days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 20 
Acclimatization Period : 7 Days 
Clinical dose   : 130mg\day 
S.No Group No of mice 
1 Vehicle control 10  (5 male, 5 female) 
2 Toxic dose 10X therapeutic dose (2.34mg) 10  (5 male, 5 female) 
 
Test Animals  
Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at Animal house, National institute of Siddha, Chennai. All the 
animals were kept under standard environmental condition (27+ or – 2 degree c).The 
animals had free access to water and standard pellet diet (Sai meera foods pvt.ltd, 
Bangalore).The principles of laboratory animal care were followed and the  
Institutional ethical committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/December/IAEC 2011) 
Route of administration: 
Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
SARVA NOI LINGA CHENDURAM  is brick red in colour .The test 
substance was insoluble in water.  In order to obtain and ensure the uniformity in drug 
distribution, the drug was dissolved by Normal solution (10%).  
Administration of doses: 
Sarva noi linga Chenduram was suspended in aqueous normal saline  
solution (10%), with uniform mixing and it was administered to the group’s in a 
single oral dose. The control groups  received equal volume of the vehicle. The 
animals were weighed before giving the drug. The dose level was calculated 
according to body weight, and surface area. Since the clinical dose was 130 mg\day. It 
was converted to animal dose (2.34 mg) and then administered. The principle of 
laboratory animal care was followed. 
Observations 
Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. Animals were observed 
individually. Visual observations included skin changes, alertness, grooming, 
aggressiveness, sensitivity to sound, touch and pain, restlessness, tremors, convulsion, 
righting reflex, gripping reflex, pinna reflex, corneal reflex, writhing reflex, papillary 
reflex ,urination, salivation, lacrimation for first 4 hrs, then periodically during the 
first 24 hrs. Animals were observed for body weight and mortality for 14 days. If 
animals dye during the period of study, the animals were sacrificed. At the end of the 
14
th
 day all animals were sacrificed and necroscopy was done. 
Body Weight 
Individual weight of animals were determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At 
the end of the test surviving animals were weighed and sacrificed. 
Results: Sarva noi linga Chenduram at the dose 2.34mg/animal did not 
exhibit any mortality in mice. 
No behavior changes were noted for the first 4 hours and for the next 24 hours 
and throughout the study period of 14 days. No weight reduction was noted before 
and after the acute study duration. Reflexes were found to be normal before and after 
the study. All other observations were found to be normal before and after the study. 
In Necropsy, the organs of the animal such as Liver, Heart, Lungs, Pancreas, Spleen, 
Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared normal. 
  
SUB ACUTE  TOXICITY STUDY OF SARVA NOI  LINGA CHENDURAM 
[WHO guidelines, 1993] 
Animals             : Male and Female Wister albino rats 
Age                    : 6-8 weeks 
Weight   : 150-200 gms 
Gender   :  Both male and female 
Number of animals   : Rat: 40 
Acclimatization period : 28 Days 
Clinical dose   : 260mg\day 
Clinical duration  : 28 days 
 
Animal source:      
   Test animals were obtained from the animal laboratory of the 
King institute, Chennai, and stocked at national institute of siddha, chennai. All the 
animals were kept under standard environmental condition (27+ or – 2 degree c) .The 
animals had free access to water and standard pellet diet (Sai durga foods pvt.ltd, 
Bangalore). The principles of laboratory animal care were followed and the 
Institutional ethical committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/December/IAEC 2011) 
Identification of animal:  
   By cage number, animal number and individual marking on fur. 
Housing and Environment: 
   The animals were housed in polypropylene cages provided with 
bedding of husk .Dark and light cycle each of 12 hours. 
 
    S.No 
                 
             Group 
      
     No of Rats 
       1 Vehicle control  10 (5male,5 female) 
       2 1XTherapeutic dose (4.68 mg) 10 (5male,5 female) 
       3 5XTherapeutic dose (23.4mg) 10 (5male,5 female) 
       4 10XTherapeutic dose(46.8mg) 10(5male, 5 female) 
Administration period: 
  The period of administration of the test substance to animals are 
depending on the expected period of clinical use. Since the clinical duration of the test 
drug is 28 days and as per WHO guidelines the administration period is reported to be 
1 month. 
 Dose selection: 
  The results of acute toxicity studies in Swiss albino mice indicated that 
Sarva noi linga chenduram was non toxic and no behavioral changes, mortality was 
observed. On the basis of these results, the doses were selected for the study as per 
WHO guidelines.  
Preparation and administration of dose:        
  Sarva noi linga chenduram was suspended in saline  solution.It was 
administered to animals at dose levels of 1Xtherapeutic dose (4.68mg/animal), 
5XTherapeutic dose (23.4mg/animal) and 10XTherapeutic dose (46.8mg/animal).The 
control animals were administered vehicle only. Administration was by oral (gavage) 
once a day for 30 days. 
 
METHODOLODY: 
Randomization, numbering and grouping of animal: 
  The animals were randomly divided into three groups for dosing up to 
30 days. Each group consist of 10 animals (5 per sex in each group) were allowed 
acclimatization period of 7 days to laboratory conditions prior to the initiation of 
treatment. Each animal fur  was  marked with picric acid. The females were 
nulliparous and non pregnant. 
 
OBSERVATION: 
  Experimental animals were kept under observation throughout the 
course of study for the following. 
Body weight:  
  Weight of each rat was recorded on day 1 and at weekly intervals 
throughout the course of study and at termination to calculate relative organ weights. 
From the data mean body weights and percent body gain were calculated. 
Food and water consumption: 
  The quantity of food consumed by groups consisting of an animal for 
different doses was recorded at weekly intervals. Food consumed per animal was 
calculated for control and the treated dose groups 
Clinical sings 
  All animals were observed daily for clinical sings. The time of onset 
intensity and duration of this symptom if any were recorded 
Mortality: 
  All animals were observed twice daily for mortality during entire 
course of study. 
TERMINAL STUDIES: 
 LABORATORY INVESTIGATIONS: 
  Following laboratory investigations were carried out. On day 31  
animals fasted overnight .Blood samples were collected by cardiac puncture using 
sodium heparin (200IU\ml) for blood chemistry and potassium EDTA (1.5 mg/ml) for 
hematology anticoagulant. Blood sample were centrifuged at 3000 r. p .m for 10 
minutes. 
Biochemical investigations: 
          The effect of Sarva noi  linga chenduram on certain biochemical 
parameters were examined and compared with those of the control group. The blood 
samples collected with heparinized bottles were centrifuged at 5000 rpm for 10 
minutes to obtain clear serum for the following investigation. Glucose was estimated 
using commercial Glucose estimation kit (Span Diagnostics) by the method of 
Barham et al., (1972) and Tenscher. et al., (1971),Haemoglobin PCV, RBC, 
Erythrocyte  count was estimated by Hemocytometer method of Ghai (1995). Total 
Leukocyte Count was estimated by Hemocytometer method of John (1972).Total, 
(Bilirubin test kid-malloy and evelyn 1937) direct and indirect bilirubins were 
determined. Alkaline phosphatase, Alanine amino tranferase (ALT) and Aspartate 
amino transferase (AST) were measured by using ALT and AST test kit (kind & king) 
.Total protein TP concentration was determined. Albumin was determined based on 
its reaction with bromocresol green (binding method) .Urea was determined according 
to urease –berthelot method and plasma creatinine was estimated using  jaffe reaction. 
Results of biochemical investigations conducted on day 31 revealed significant 
changes in the values of different parameters studied when compared with those of 
respective controls. 
NECROPSY:  
           All the animals were sacrificed on day 31 under ether anesthesia. 
Necropsy of all animals was carried out and the weights of the organs including liver, 
kidneys, brain, heart, and lungs were recorded. 
HISTOPATHOLOGY: 
  Tissue samples of organs from control and treated animals were 
preserved in 10% formalin for preparation of sections using microtome. The organs 
included liver, kidneys, heart, lungs and stomach of the animals were preserved and 
they were subjected to histopathological examination. 
 
  The organ pieces (3-5 micron ) were fixed in 10% formalin for 24 
hours and washed in running water for 24 hours .Samples were dehydrated in tissue 
processor and then cleaned in benzene to remove absolute alcohol .Embedding  was 
done by passing the cleared sample through three cups containing molten paraffin at 
50 degree c and then a cubical block of paraffin made by the L moulds it was 
followed by microtome and the slides were stained with haematoxylin–eosin stain 
.Stained sections of each organ were examined under light microscope at high (40X) 
power magnification. All the histo pathological slides were prepared at Dept .of. 
Pathology,Vels university,pallavaram Chennai. 
  
1.HISTO PATHOLOGY OF BRAIN. 
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2.HISTO PATHOLOGY OF HEART 
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3.HISTOPATHOLOGY OF INTESTINE 
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4.HISTOPATHOLOGY OF KIDNEY 
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5.HISTO PATHOLOGY OF LIVER 
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6.HISTO PATHOLOGY OF LUNG 
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7.HOSTO PATHOLOGY OF OVARY 
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8.HISTO PATHOLOGY OF PANCREAS 
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9.HISTO PATHOLOGY OF SPLEEN 
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10. HISTOPATHOLOGY OF STOMACH 
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11.HISTO PATHOLOGY OF TESTIS 
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                                    FIGURE.11 
TREATED on control  Group (Low dose) 
Kidney: shows normal renal tissue with glomeruli and tubules.  
Spleen: shows normal spleen with lymphoid aggregation. 
Liver: shows almost normal hepatocytes and occasional binucleate cells. 
Stomach: shows normal mucosal glands. 
Ovary: shows ovarian stroma with follicles and corpus leuteum. 
Lung: shows normal alveoli. 
Testis: shows normal tubules with spermatogenesis. 
Heart: shows normal cardiac muscle bundles. 
Brain: shows normal brain with nerve fibers and astrocytes. 
Intestine: Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
Pancreas: shows normal acini with islets of β-cells 
IMPRESSION: NORMAL STUDY 
 
  
Treated  on 5x (Mid dose) 
Brain:  
shows brain with edema, microglial proliferation, shows brain with 
micro cystic change and astrocytic proliferation, shows brain with mononuclear 
infiltrate around vessel.  
Kidney:  
shows renal tissue with focal tubular damage, interstitial inflammatory 
collection. Glomeruli shows epithelial proliferation.  
Liver:  
shows hepatocytes with focal mild fatty change.  
Spleen: 
 shows congestion with lymphoid hyperplasia.  
Stomach:  
shows near normal mucosal gland with mild exudates. 
Lung:  
shows congested alveolar wall with mild thickening and mild 
emphysematous changes.  
Pancreas:  
shows pancreas with acini and normal islets.  
Testis:  
shows normal tubules with spermatogenesis. 
Heart:  
shows congestion and mild inflammatory infiltration in between 
cardiac muscle bundles. 
Ovary:  
shows ovarian stroma with follicles and corpus leuteum. 
Intestine:  
Shows normal Intestinal mucosal lining with mild exudates. 
 
Bone:   Shows normal osteocytes 
 
IMPRESSION: NORMAL STUDY 
  
TREATED 10x (High dose) 
Stomach: shows stomach with superficial erosion and congestion.  
Heart: shows hypertrophic cardiac muscle bundles.  
Spleen: shows lymphoid hyperplasia. 
Brain: shows brain with edema. Astrocytes show degenerative changes.shows brain 
with pyknotic irregular nucleus, shows brain with vesicular nuclei and micro cystic 
changes.  
Liver: shows marked dilatation of sinusoids, degeneration of hepatocytes, necrosis.   
Kidney: shows renal tissue with tubular epithelial damage.  
Pancreas: shows atrophic islet cells. 
Testis: Giant cells were formed in the lumen of the seminiferous tubules and the 
spermatogenic cells degenerated. Lung: shows congestion, narrowed alveolar space 
and thickened alveolar     wall. 
Ovary: shows ovarian follicles and corpus leuteum. 
Intestine:Shows normal Intestinal mucosal lining with mild exudates. 
Bone: Shows normal osteocytes 
IMPRESSION: NORMAL STUDY 
Results:  
 No weight loss, abnormal animal behaviours, metabolic functions [urination, 
lacrimation, defaecation etc.,] and mortality were noted. 
 In necropsy of the animal organs showed normal appearance and weight. 
 All Haematological and biochemical parameters were within normal limits. 
 The stastical report of the Haematological and Biochemical datas did not show 
any significant difference, between the control and test groups.  
 In Histopathological studies, No abnormal findings were observed in the organs 
such as Heart, Liver, Lungs, Kidney and Stomach in X, 5X and 10X compared 
with control group. 
          
 
 
 
 
 
 
              
 
     Annexure II 
   Bio Chemical                           
             Analysis 
  
BIO -CHEMICAL ANALYSIS
 
OF SARVA NOI  LINGA CHENDURAM –  
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
                Appearance of sample Red in colour 
S.
no 
EXPERIMENT OBSERVATION INFERENCE 
1. Solubility: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little (500mg) of the sample is 
shaken well with con. HCl/Con. 
H2So4 
 
 
 
 
Sparingly soluble 
 
 
 
 
Presence of Silicate 
2. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube 
and heated gently at first and then 
strong. 
 
 
 
White fumes 
evolved 
 
 
 
Presence of 
Carbanate 
3. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with 
con. HCl in a watch glass and 
introduced into non-luminous part 
of the Bunsen flame. 
 
 
 
No Bluish green 
flame appeared 
 
 
 
Absence of copper 
4. Ash Test: A filter paper is soaked 
into a mixture of sample and dil. 
cobalt nitrate solution and 
introduced into the Bunsen flame 
and ignited 
 
Yellow colour 
flame appeared 
 
Presence of Sodium 
 
  
Preparation of Extract: 
5gm of Sarva noi  linga chenduram is weighed accurately and placed in a 
250ml clean beaker and added with 50ml of distilled water. Then it is boiled well for 
about 10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and made 
up to 100ml with distilled water. 
 
 I.Test For Acid Radicals 
 
S.
no 
EXPERIMENT OBSERVATION INFERENCE 
1 Test For Sulphate :  
2ml of the above prepared extract is 
taken in a test tube to this added 2ml 
of 4%dil. ammonium oxalate 
solution. 
 
 
No cloudy 
appearance  
appeared 
 
 
Absence of 
sulphate 
2 Test For Chloride: 
2ml of the above prepared extracts is 
added with 2ml of dil-HCl is added 
until the effervescence ceases off. 
 
 
No cloudy 
appearance  
appeared 
 
 
Absence of 
chloride 
3 Test For Phosphate: 
2ml of the extract is treated with 2ml 
of ammonium molybdate solution 
and 2ml of con.HNO3 
 
 
Mild yellow 
appearance present 
 
 
Presence of 
Phosphate 
4 Test For Carbonate:  
2ml of the extract is treated with 
2mldil. magnesium sulphate solution 
 
Cloudy appearance 
present  
 
Presence of 
Carbanate 
5 Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated. 
 
 
No cloudy 
appearance 
 
 
Absence  of     
fluoride and   
oxalate 
  
6 Test For Nitrate: 
1gm of the substance is heated with 
copper turning and concentrated 
H2SO4 and viewed the test tube 
vertically down 
 
 
No brown gas 
evolved 
 
 
Absence of nitarte 
7 Test For Sulphide:  
1gm of the substance is treated with 
2ml of con. HCL 
 
No Rotten Egg 
Smelling gas  
evolved 
 
Absence of 
sulphide 
8 Test For Nitrite: 
  3drops of the extract is placed on a 
filter paper, on that-2 drops of 
dil.acetic acid and 2 drops of dil. 
Benzidine solution is placed. 
 
 
No characteristic 
changes  
 
 
Absence of Nitrite 
9 Test For Borate: 
  2 Pinches (50mg) of the substance 
is made into paste by using 
dil.sulphuric acid and alcohol (95%) 
and introduced into the blue flame. 
 
 
Bluish green colour 
flame not appeared 
 
 
Absence Of Borate 
 
II. Test For Basic Radicals 
 
1 Test For Lead: 
        2ml of the extract is added with 
2ml of dil.potassium iodine solution. 
 
 
No Yellow 
Precipitate is 
obtained. 
 
 
Absence of lead 
2 Test For Copper: 
 One pinch (50mg) of substance is 
made into paste with con. HClin a 
watch glass and introduced into the 
non-luminuous part of the flame. 
 
 
Blue  colour    
 
precipitate formed. 
 
 
 
Presence of Copper 
 
3 Test For Aluminium: 
  To the 2ml of extract dil.sodium 
hydroxide is added in 5 drops to 
excess. 
 
 
Yellow colour 
appeared 
 
 
 
Presence of 
Aluminium 
4 Test For Iron: 
a. To the 2ml of extract add 
2ml of thiocyanate ammonium 
solution 
b. To the 2ml of extract add 
2ml of  thiocyanate ammonium 
solution and 2ml  of con HNO3 . 
 
 
  
 
Red colour 
appeared  
 
 
 
 
 Presence of iron  
5 Test For Zinc:  
      To 2ml of the extract dil.sodium 
hydroxide solution is added in 5 
drops to excess and dil.ammonium 
chloride is added.  
 
 
White precipitate is 
not formed  
 
 
Absence of Zinc 
6 Test For Calcium:  
      2ml of the extract is added with 
2ml of 4% dil.ammonium oxalate 
solution  
 
Cloudy appearance 
and white 
precipitate is 
obtained 
 
 
Presence of 
Calcium  
7 Test For Magnesium:  
To 2ml of extract dil.sodium 
hydroxide solution is added in drops 
to excess. 
 
 
White precipitate is 
obtained 
 
 
Presence Of 
Magnesium 
8 Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
 
 
No Brown colour 
appeared 
 
 
Absence of 
Ammonium 
9 Test For Potassium:  
   A pinch (25mg) of substance is 
treated off with 2ml of dil.sodium 
nitrite solution and then treated with 
2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
 
 
 
No yellowish 
precipitate is 
obtained 
 
 
 
Absence of  
Pottasium 
10 Test For Sodium: 
   2 pinches (50mg) of the substance 
is made into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
 
Yellow colour 
flame appeared 
Presence of sodium 
11 Test For Mercury:  
   2ml of the extract is treated with 
2ml of dil.sodium hydroxide 
solution.  
 
Yellow precipitate 
is obtained 
 
Presence of 
Mercury 
12 Test For Arsenic:  
   2ml of the extract is treated with 
2ml of dil.sodium hydroxide 
solution. 
 
No Brownish red 
obtained  
 
Absence of 
Arsenic 
                                         III.Miscellaneous 
1  Test For Starch:  
 2ml of extract is treated with weak 
dil.iodine solution  
 
 
No blue colour 
devolopped 
 
 
Absence of  Starch 
2 Test For Reducing Sugar: 
 
5ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The 
colour changes are noted 
 
 
 
Brick red colour 
not devolopped  
 
 
 
Absence of 
reducing sugar 
 
3 Test For The Alkaloids: 
a) 2ml of the extract is treated with 
2ml of dil.potassium lodide solution. 
b)  2ml of the extract is treated with 
2ml of dil.picric acid. 
c)  2ml of the extract is treated with 
2ml of dil.phosphotungstic acid. 
 
 
 
Yellow colour not 
developed 
 
 
 
Absence of 
alkaloid 
4 Test For Tannic Acid:  
  2ml of extract is treated with 2ml 
of dil.ferric chloride solution 
 
 
No black 
precipitate obtained 
 
 
Absence of Tannic 
acid 
5 Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
diluted Potassium permanganate 
solution is added.  
 
 
Potassium 
permanganate 
solution is 
decolourised 
 
 
Presence of 
Unsaturated 
compounds 
6 Test For Amino Acid: 
    2 drops of the extract is placed on 
a filter paper and dried well. 20ml of 
Biurette reagent is added. 
 
 
Violet  colour  not 
developed 
 
 
Absence of  
 
Aminoacid 
7 Test For Type Of Compound: 
    2ml of the extract is treated with 2 
ml of dil.ferric chloride solution.  
 
 
No  Brown  colour 
developed 
 
 
Absence  of  Oay  
quinole, Pinephrine  
and  Pyro catechol 
 
  
Table-1 
 
 Colour  characters of Sarva Noi Linga  Chenduram. 
 
 
S No 
 
Solvent used 
 
Under ordinary light 
 
Under ultra violet light 
 
1 Powdered  material Dark Brown Dark Brown 
 
 
 
Table-2 
 
 Physicochemical properties of Sarva Noi Linga  Chenduram. 
 
 
S No. 
 
Parameters  
Values 
obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value  9.15 Lead BDL 
2 Acid insoluble ash  0.77 Cadmium BDL 
3 Water soluble ash  5.63 Mercury 4.251mg/L 
4 Moisture content  10.24 Arsenic BDL 
 
 
 
 
Table-3 
 
 Colour, nature and percent yields of extracts of  Sarva Noi Linga Chenduram 
 
 
S.no. 
 
Extract 
Solvents 
 
Colour 
 
Nature 
 
 
         % 
Yield(w/w) 
 
SEM-Micro 
graph 
partical size 
range in 
micron 
 
pH 
1 Water Dark 
brown 
Solid      49 1 – 2.5 micron 8.5 – 
8.7 
 
Preliminary Qualitative Phyto chemical tests procedure and interpretation of 
     results 
 
S.NO PROCEDURE INFERENCE 
1. Calcium    Presence  of  Calcium 
2. Sulphate    Absence  of  Sulphate 
3. Chloride    Absence  of  Chloride 
4. Carbonate    Presence of  Carbonate 
5. Starch    Absence of  Starch 
6. Iron     Presence   of  Iron  
7. Phosphate    Presence  of  Phosphate 
8. Tannic acid    Absence  of  Tannic acid 
9. Aluminium    Presence  of  Aluminium 
10. Magnesium    Presence  of  Magnesium 
11. Ammonium    Absence  of   Ammonium 
12. Mercury    Presence  of  Mercury 
13. Alkaloids    Absence  of  Alkaloids 
14. Reducing Sugar    Absence  of  Reducing sugar 
15. Silicate    Presence  of  Silicate 
16. Copper    Absence  of  Copper 
17. Sodium    Presence  of  Sodium 
18. Lead    Absence  of  Lead 
    19. Fluoride And Oxalate    Absence  of  Fluoride and Oxalate 
    20. Unsaturated compounds    Presence of unsaturated compunds 
  
  
 
               PARTICLE  SIZE OF SARVA NOI  LINGA CHENDURAM 
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     Annexure IV 
  Proforma  
  
                     NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
   DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
  FORM I  SCREENING & SELECTION PROFORMA 
 REG NO: 32101203 /2012-13 
 
1. SI NO______    2 OP /IP NO:__________ 
 
3.NAME :______________________________ 4. AGE/SEX________5.RELIGION : H / C / M / O 
 
6.OCCUPATION / INCOME : ____________ 
 
 INCLUSION CRITERIA 
 
 Age 30-60 yrs        Yes/No 
 Sex         M/F 
 Clinical symptoms of pain and swelling present in knee joints 
Crepitations,stiffness,restricted movements, minimal tenderness etc Yes/No 
 Patient willing to under go lab and radiological investigations  Yes/No 
 Patient willingness for consent to include in the trial   Yes/No 
 EXCLUSION CRITERIA 
 
ADMITTED TO TRAIL :    YES         NO         If Yes Serial NO:  
Date: 
 
Station: 
                                                                                     
Signature of  the Investigator:                                                        
 
Signature of the Lecturer:      
         
        Signature of the HOD 
Rheumatoid 
arthritis 
Y/N Gouty arthritis Y/N Chickun gunya Y/N 
Tuberculosis of 
knee joints 
Y/N History of trauma Y/N Diabetes mellitus Y/N 
Hypertension Y/N Cardiac diseases Y/N Any other illness Y/N 
 NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
      FORM l A   - HISTORY PROFORMA ON ENROLLMENT 
 
REG NO: 32101203/2012-13 
 
1. Serial No :________________   2. OP/IP No:________________________________ 
       
3. Name: ___________________________________  4. Gender:   Female/male 
 
5. Age (years): _______________DOB            
      Date       Month            Year 
6.Address:______________________________ _______________________________ 
                  ______________________________ _______________________________ 
 
7.A.Occupation:--------------------------------    B. Nature of work--------------------------- 
 
8. Educational  Status: A) Illiterate        B)Literate        9.Height:   cms 10.Weight:      kg     
   
11. Complaints and Duration:   
________________________________________________________________________ 
 
________________________________________________________________________ 
 
12. Habits of 
 
A) Smoking  1. Yes; duration ________ years; Number - 2.No 
B) Alcoholism  1. Yes; duration ________ years; Quantity-ml 2.No 
C) Tobacco chewing 1. Yes; duration ________ years; 2.No 
D) Betel chewing 1. Yes; duration ________ years;   2.No 
 
13.Dietry style A.Pure vegetarian           B.Non-vegetarian            C. Mixed diet 
 
14.Treatment  History:  
Had the patient been treated before with allopathy drug? A)Yes            B)No 
15. Menstrual Historty: 
 
Date: 
 
Station:  
 
Signature of the investigator 
              
Signature of the lecturer                                                 
       Signature of  HOD          
        
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
   DEPARTMENT OF MARUTHUVAM 
 
 PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
 
        FORM II  CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
    1. S NO -----------     2. OP/IP NO --------------------  REG NO: 32101203/2012-13 
    3.  NAME -----------   4.GENDER M/F   5. DATE OF  ASSESSMENT   :------------ 
    
Initial (0
th
 day)             12
th 
day          24
th  
day          36
th
 day       48
th
 day 
 
SIDDHA SYSTEM OF EXAMINATION 
1. ENNVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 
 I. NAADI: [PULSE PERCEPTION] 
     
 
  
II. NAA:[TONGUE] 
 
 
 
 
0th Day 12th Day 24th Day 36th Day 48th Day 
Colour Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Dark / 
Yellow/ 
Red / Pale/ 
Normal 
 
Taste Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Sweet/ 
Bitter / 
Sour 
Pungent/ 
None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Naadi 0
th
 
day 
12
th 
day
 
24
th 
day
 
36
th 
day 
48
th
 
day 
Naadi 0
th
 
day 
12
th 
day 
24
th
 
day 
36
th
 
day 
48
th
 
day 
Vali      Iyya vali      
Azhal      Vali Iyyam      
Iyyam      Azhal 
Iyyam 
     
Vali 
azhal 
     Iyya Azhal      
Azhal 
vali 
           
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present 
/Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
III.NIRAM: [COMPLEXION]    
 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
nd
 Day 
Dark/ 
Yellowtinted/ 
Wheatish brown/ 
Pale 
Dark/ 
Yellowtinted/ 
Wheatish brown/ 
Pale 
Dark/ 
Yellowtinted/ 
Wheatish brown/ 
Pale 
Dark/ 
Yellowtinted/ 
Wheatish brown/ 
Pale 
Dark/ 
Yellowtinted/ 
Wheatish 
brown/ Pale 
 
IV.MOZHI: [VOICE] 
 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
nd
 Day 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Lowpitched 
 
V.VIZHI: [EYES] (Lower palpabrel conjunctiva)   
 
0
th
 Day 12th day 24
th
 Day 36
th 
Day 48
nd
 Day 
Yellow 
Red 
/ Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
Yellow 
Red/ 
Pale/Normal 
   
VI. MALAM; [BOWEL HABITS / STOOLS] 
 
 0
th
 Day 12
th
 Day 24 
th
 Day 36
nd
 Day 48
th
 day 
Colour Dark/ 
Yellow/ 
Pale/Others 
Dark/ 
Yellow/ 
Pale/Others 
Dark/  
Yellow 
Pale/Others 
Dark/ 
Yellow/ 
Pale/Others 
Dark/  
Yellow/ 
Pale/Others 
Consistency Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Solid/ 
Semisolid 
Watery 
Stool  bulk                          Normal/
Reduced 
Normal 
/Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
 
VII. URINE EXAMINATION:  
   
 
 
 
VIII. SPARISAM: [PALPATORY  PERCEPTION] 
 
0
th
 Day 12
th
 Day 24
th
 Day 36
th
 Day 48
nd
 Day 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
Warmth/ 
Cold/ 
Normal/ 
Sweat 
 
THEGI: [ TYPE OF BODY CONSTITUTION]  
   
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
6.NILAM: [ LAND WHERE PATIENT LIVED MOST] 
 
  Kurinji               Mullai                 Marutham             Neithal              Palai 
 
 (Hilly terrain)      (Plains)                (Coastal belt)        (Aridregions)    (Forestrange) 
  
NEER 
KURI 
0
th
 Day 12
th
 Day 24 
th
 Day 36
nd
 Day  
Niram 
[Colour]   
White/ 
Yellowish/ 
Straw 
coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw coloured/ 
Crystal clear 
White/ 
Yellowish/ 
Straw 
coloured/ 
Crystal clear 
Manam 
[Odour] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Nurai 
[Froth] 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai 
[Sp.gra]                                
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal 
[Deposits] 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Present/ 
 Absent 
Volume   Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
NEIKURI 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Serpentine fashion      
Annular/Ringed fashion      
Pearl beaded fashion         
Mixed fashion      
Other fashion      
7.KAALAM 
 
Kaarkalam   Pinpanikalam      
Koothirkalam   Ilavenil 
Munpanikalam   Muthuvenil 
 
8. GUNAM 
Sathuvam                        Rasatham                       Thamasam 
 
 
IMPORIGAL (SENSORY ORGANS) 
 
 
 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Mei  
(Skin) 
     
Vaai 
(Buccal 
Cavity) 
     
Kann 
 (Eye) 
     
Mooku 
(Nose) 
     
Sevi(Ear)      
7. KANMENTHIRIYAM ( MOTOR ORGANS) 
 
 
8. KOSANGAL(Sheath)   
 
Kosangal 
 
0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Annamaya Kosam 
 
     
Pranamaya kosam      
Manomaya kosam       
Vignanamaya kosam  
 
     
Ananthamaya kosam      
 
12. MUKKUTRAM:[AFFECTION OF THREE HUMORS] 
A)VATHAM: 
 
 
Vatham  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Praanan      
Abaanan      
Samaanan      
Udhaanan      
Viyaanan      
Naagan      
Koorman      
Kirukaran      
Devathathan      
Dhananjeyan      
Kanmenthiriyam  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Kai (upper limb)      
Kaal (lower limbs )      
Vaai   (buccal cavity)      
Eruvai (excretory 
organs) 
     
Karuvai  
(reproductive organs) 
     
 B) PITHAM: 
 
Pitham 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Analapitham      
Prasakam      
Ranjakam      
Aalosakam      
Saathakam      
 
C) KABAM: 
 
Kabam  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Avalambagam      
Kilethagam      
Pothagam      
Tharpagam       
Santhigam      
 
13. SEVEN DHATHUS: (7 SOMATIC COMPONENTS)  
 
Udal thathukkal  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
Saaram[Chyme]      
Senneer[Blood]       
Oon[Muscle]      
Kozhuppu[Fat]      
Enbu[Bones]      
Moolai 
[Bonemarrow] 
     
Sukkilam/Suronith
am[Genital 
discharges] 
     
14. SYSTEMIC EXAMINATION: 
 
 
 
 
15. GENERAL EXAMINATION: 
 
General Examination: 
 
0
th
 day 12
th
 day 24
th
 day 36
th 
day 48
th
 day 
Height (cms)      
Weight (kg)      
BMI      
Temperature(°F)         
Pulse rate (pe rmin)      
Heart rate (per min)      
Respiratoryrate(permin)      
Blood pressure(mm/Hg)      
Pallor      
Jaundice      
Cyanosis      
Lymphadenopathy      
Pedal edema      
Clubbing      
Jugular venous pulsation      
 
Systemic examination 0
th
  
day 
12
th 
 day 
24
th
  
day 
36
th 
 day 
48
th
 day 
Locomotor system      
Cardio Vascular System  
 
    
Respiratory system       
 
    
Gastro Intestinal system     
 
    
Central Nervous System         
 
    
Urogenital system      
Endocrine System      
16. CLINICAL SYMPTOMS 
 
CLINICAL EXAMINARTION OF KNEE JOINT   
 
I. INSPECTION      
 
II. PALPATION 
S.no Palpations  0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
1 Tenderness      
2 crepitation      
3 warmth      
 
S.no CLINICAL 
SYMPTOMS 
0 th 
day 
12
th
 
day 
24
th
 
day 
36
th
 
day 
48
th
 
day 
1 Pain       
2 Swelling      
3 Early morning stiffness      
4 Restricted movements 
(Fully/Partial/No) 
     
5 Minimal tenderness      
6 Crepitations      
S.no Inspection 0
th
 day 12
th
 day 24
th
 
day 
36
th
 day 48
th
 day 
1 Attitude:      
 
2 Shape       
3 Knee joint  
swelling 
     
4 Skin over the  
knee joints 
     
5 Muscle 
 wasting  
     
6 Deformity Genu 
varum                                  
     
MOVEMENTS 
 
 
 
Date : 
 
Station: 
 
 
Signature of the Investigator: 
 
  
 
Signature of the Lecturer:     
 
 
     Signature of the HOD 
 0
th
 day 12
th
 day 24
th
 day 36
th
 day 48
th
 day 
A.PAIN 
Onset:    
Sudden/Gradual  
     
B.Early morning  
Stiffnes 
(Present/absent) 
     
C.Nature of pain 
(Mild/ Moderate/ 
Severe)                                                                                                                           
     
D.Aggravating   
factor-   Movement  
(Yes/No) 
     
E.Relieving factor –
Rest 
  (Yes/No) 
     
F.Tenderness 
(Present/absent) 
     
G.Restriction:  
(Fully/Partial/No)  
     
  NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
      
        FORM III 
   LABORATORY PARAMETERS-CHART 
  
1. OP/IP No: ____________  2.S. No:_____ 3.Reg no:  32101203/2010-11 
4. Name: ____________________________ 5. Age/sex : ______________   
 
  
BLOOD INVESTIGATION NORMAL VALUES 
BEFORE 
TMT 
 
AFTER  
  TMT 
HB( gms%) 
M:13-18 
W:11-16 
  
 
T.RBC(million cells /cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
 
ESR (mm) 
½ hr. 
M:0-10 
W:0-20 
  
1 hr.   
T.WBC (cells /cu.mm)       4000-11000   
DIFFERENTIAL 
COUNT (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Esonophils 1-6   
Basophils 0-1   
 Blood Investigation Normal Values 
Before 
TMT 
 Date: 
After 
 TMT 
Date 
Blood 
glucose 
(mg/dl) 
Fasting 70-100   
PP 80-140   
Random 100-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-250   
HDL 30-60   
LDL Upto 130   
VLDL 40   
TGL Upto 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
LFT 
(mg/dl) 
Total bilirubin 0.3-1   
Direct bilirubin 0.1-0.3   
Indirect bilirubin 0.2-0.8   
Serum total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
Serum calcium 9-11   
Serum phosphorous 2-5   
SGOT (IU/L) 6-18   
SGPT (IU/l) 3-26   
Alkaline phosphatase 
mg/dl 
3-12   
  
 
 
Specific  investigation 
Before TMT 
Date: 
After TMT 
Date: 
RA factor   
CRP   
URINE 
INVESTIGATION 
Before TMT(with Date) After TMT (With Date) 
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
NEIKURI   
MOTION TEST   
Ova   
Cyst   
Occult blood   
X ray changes 
 
 
Before TMT 
(with Date) 
After TMT 
(With Date) 
X ray of affected  knee      
            joints  
  
 
 
 
 
 
Date : 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:    Signature of the HOD 
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AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
 
      FORM IV-E 
 
        WITHDRAWAL FORM 
 
 
S. NO:________  OPD/ IPD NO:______________  REG  NO: 32101203/2012-13 
NAME:_______________________________  AGE/SEX :___________________ 
  
DATE OF TRIAL COMMENCEMENT:_____________________ 
 
DATE OF WITHDRAWAL FROM THE TRIAL:_____________ 
 
REASONS FOR WITHDRAWAL: 
 
 Long absence at reporting     Yes  / No 
 Irregular treatment:       Yes  /  No 
 Shift of locality      Yes  / No 
 Increase in severity of symptoms    Yes  / No 
 Development of severe adverse drug reactions  Yes  / No 
 
 
Date :      
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         
 
    Signature of the HOD 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
   FORM IV –A (DRUG COMPLIANCE FORM) 
 
S. NO:________ OPD/ IPD NO:______________  REG  NO: 32101203/2012-13 
NAME:____________________________  AGE/SEX :______________________ 
Name of the drug : Sarva noi linga chenduram ( internal ) 
           Maasha  thylum  ( external) 
Drugs issued: (Nos)     Drugs issued:   (Nos) 
Drugs returned:(Nos)     Drugs returned:  (Nos)   
  
Date :                  
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         
 
    Signature of the HOD 
S.NO DATE 
DRUG TAKEN TIME 
MORNING/TIME EVENING/TIME 
Day 1      
Day 2      
Day 3      
Day 4      
Day 5      
Day 6      
Day 7      
Day 8      
Day 9      
Day 10      
Day 11      
Day 12      
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
    FORM IV –A (DRUG COMPLIANCE FORM) 
 
S. NO:_______ OPD/ IPD NO:_______________  REG  NO: 32101203/2012-13 
NAME:_________________________________ AGE/SEX :___________________ 
Name of the drug : Sarvo noi  linga chenduram ( internal ) 
          Maasha thylum  ( external) 
Drugs issued: (Nos)     Drugs issued:   (Nos) 
Drugs returned:(Nos)     Drugs returned:  (Nos)   
 
Date :                  
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                        Signature of the HOD 
DAYS 
                 DATE  
 
DRUG TAKEN TIME 
MORNING/TIME EVENING/TIME 
Day 13      
Day 14      
Day 15      
Day 16      
Day 17      
Day 18      
Day 19      
Day 20      
Day 21      
Day 22      
Day 23      
Day 24      
NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
  FORM IV –A (DRUG COMPLIANCE FORM) 
 
S. NO:________ OPD/ IPD NO:______________  REG  NO: 32101203/2012-13 
NAME:____________________________________ AGE/SEX :_______________ 
Name of the drug : Sarva noi  linga chenduram ( internal ) 
           Maasha thylum            ( external) 
Drugs issued:  (Nos)     Drugs issued:   (Nos) 
Drugs returned: (Nos)     Drugs returned:  (Nos)                                                         
 
Date :    
               
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         
    Signature of the HOD 
S.NO DATE 
DRUG TAKEN TIME 
MORNING/TIME EVENING/TIME 
Day 25      
Day 26      
Day 27      
Day 28      
Day 29      
Day 30      
Day 31      
Day 32      
Day 33      
Day 34      
Day 35      
Day 36      
 NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   POTHUMARUTHUVAM 
 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA 6NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
  FORM IV –A (DRUG COMPLIANCE FORM) 
 
S. NO:________ OPD/ IPD NO:______________  REG  NO: 32101203/2012-13 
NAME:__________________________________ AGE/SEX :_______________ 
Name of the drug:  Sarva  noi linga chenduram ( internal ) 
          Maasha thylum  ( external) 
Drugs issued:  (Nos)     Drugs issued:   (Nos) 
Drugs returned:          (Nos)    Drugs returned:  (Nos)    
Date :                  
Station: 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                         
    Signature of the HOD 
     
DAYS DATE 
DRUG TAKEN TIME 
MORNING/TIME EVENING/TIME 
Day 37      
Day 38      
Day 39      
Day 40      
Day 41      
Day 42      
Day 43      
Day 44      
Day 45      
Day 46      
Day 47      
Day 48      
   §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
«Æø ¸£øÅ¡Ô §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý ( º÷Å §¿¡ö þÄ¢í¸ ¦ºóàÃõ ÁüÚõ Á¡„ ¨¾Äõ - 
¯ÙóÐ ¨¾Äõ ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ  ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
 FORM  IV B  ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ : Dr.R. Ã¡¾¡¸¢Õ‰½ý 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷  : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
      ¾¡õÀÃõ º¡É¼§¼¡Ã¢Âõ 
  ¦ºý¨É- 47 
Dr.Ã¡¾¡¸¢Õ‰½ý ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕ¸¢§Èý. «Æø 
¸£øÅ¡Ô ±ýÛõ §¿¡Â¡ÉÐ ¦ÀÕãðÎ¸¨Ç À¡¾¢ìÌõ §¿¡Â¡Ìõ. þó§¿¡Â¡ÉÐ ãðÎ¸û ¾¢Á¢÷óÐ 
¸¡Ïõ, ãðÎ¸Ç¢ø Å£ì¸õ,ÅÄ¢ ¿¼ì¸ ÓÊÂ¡¨Á, ¿¼ìÌõ §À¡Ð ¿ð¨¼Ô¨¼¾ø §À¡ýÈ ´Ä¢, º¢Ä 
§¿Ãí¸Ç¢ø ÍÃõ ¸¡Ï¾ø, ¬¸¢Â ÌÈ¢Ì½í¸û ¸¡Ïõ. þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø 
ÀÄ º¢ò¾ ÁÕóÐ¸û ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ 
ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø º÷Å §¿¡ö þÄ¢í¸ ¦ºóàÃõ þó§¿¡öìÌ ÅÆí¸ 
ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ ÁüÚõ ÁÕòÐÅ ÀÂý¸û 
«¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û 
þó¾ ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 48¿¡ð¸û ¬Ìõ. 7 
¿¡ð¸ÙìÌ ¦¾¡¼÷óÐ ÁÕóÐ ¯ñÎ À¢ý 5 ¿¡ð¸ÙìÌ ÁÕóÐ ¯ñ½¡Áø Àò¾¢Âõ ¸¡ì¸ §ÅñÎõ, 
þõÓ¨ÈôÀÊ ( 7+5) ±É þýÛõ 36 ¿¡ð¸ÙìÌ ¦¾¡¼Ã §ÅñÎõ, ¦ÅÇ¢ ÁÕó¾¡¸ Á¡„ ¨¾Äõ( 
¯ÙóÐ ¨¾Äõ ) 50 Á¢Ä¢ 48 ¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å §ÅñÎõ. ¦ÅÇ¢ 
§¿¡Â¡Ç÷¸û 12 ¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 48¿¡ð¸û ÁÕóÐ ¯ð¦¸¡ûÙõ 
¸¡Äõ ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý ÓÊ×¸Ç¢ý 
«ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ. 
 
þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. ¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ 
¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç 
¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ §¸ð¸ôÀÎõ 
§¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ 
±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û 
¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× §Áü¦¸¡ûÇôÀÎõ. «Æø ¸£øÅ¡Ô §¿¡öì¸¡É Ò¾¢Â 
ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ, þó¾ 
¬öÅ¢ø, ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø Å¡ö ¿¡üÈõ, ¯½× ¯ñ½ ÓÊÂ¡¨Á, ¯Á¢ú ¿£÷ ÅÊ¾ø, 
Å¡ö, ¦¾¡ñ¨¼, ÁüÚõ ÅÂ¢üÈ¢ø ±Ã¢îºø §À¡ýÈ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ þÕìÌõ 
Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø 
«¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã ¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, 
±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø Å¢Ä¸¢ì¦¸¡ûÇ×õ, ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ 
þó§¿¡öì¸¡É ÅÆì¸Á¡É ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
 
þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ 
þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. 
«¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý ¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î 
ÅÆí¸ôÀÎõ. «ó¾ì ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ¾¸Åø ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û.    
    
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û ¦ÀÈ §ÅñÎ¦ÁÉ 
Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ 
§ÁüÀÊôÒòÐ¨È Á¡½Å÷ Dr.R. Ã¡¾¡¸¢Õ‰½ý ¬¸¢Â ±ý¨É 9884400971 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò 
¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 ±ýÈ 
±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.   
   NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
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THYLUM( EXTERNAL) 
FORM IV  B – INFORMATION SHEET 
Name of the Principal Investigator: Dr.R.Radha krishnan 
Name of the Institution                   : National Institute of Siddha, Tambaram Sanatorium 
                                                                Chennai-47. 
 I, Dr.R.Radhakrishnan Studying M.D(S) in National Institute of Siddha, Chennai. The disease called azhal 
keel vayu(osteo arthritis )  Osteo arthritis (OA) is a most common persistent  degenarative  arthritis, occurring 
throughout the world and in all ethnic groups It includes the symptoms like, pain in the knee joint, swelling, 
restricted movements, crepitation.This condition is being treated is NIS with many siddha formulations. As a 
part of M.D(S) research programme and developing new efficacious medicine, we propose to study the Sarva 
noi linga chenduram and  maasha thylum[ulunthu thylum) formulation for treating the condition. This 
formulation has been mentioned in siddha literature and empirical evidence with contemporary tools is 
required for documentation. You can receive medicines free of cost. sarva noi linga chenduram(Internal 
medicine-130mgs BD with Honey  for 28 days in a duration of 48 days) and Maasha  Thylum (External 
medicine ).  The diagnosis tests will be carried out free of cost. We will assess the effect of treatment after 
completion of 48 days of treatment using clinical and lab parameters. 
 
 In this regard, we need to ask you few questions. We will maintain confidentiality of your comments and data 
obtained from you. There will be no risk of disclosing your identity and no physical, psychological or 
professional risk is involved by taking part in this study. 
 
 Taking part in this study is voluntary. No compensation will be paid to you for taking part in this study. You 
can choose not to answer any specific question. There is no specific benefit for you if you take part in the 
study, but you will be under our clinical monitoring and specific attention will be given for your health. 
Taking part in the study may be of benefit to the community, as it may help us to develop medicine for azhal 
keel vayu. In case of any adverse symptoms during the treatment viz, apthous ulcers, difficulty to take food 
and water sometimes to speak, bad breath, thickened salivary secretion  and burning sensation if felt in 
mouth, throat and stomach which is expected for few .patients during the treatment, shall be reported to PIs 
and care will be taken in NIS for relief. You can withdraw from the study at the midst of treatment period, if 
you are not interested to continue and you will receive our usual treatment without condition. 
 
 
 The information we will collect in this study, will remain between you and the principal investigator. We will 
ask you a few questions through questionnaire. We will not write your name on different forms which sent to 
different investigating/analysis sections and we will use a code instead given by the principal investigator. 
Only the principal investigator will know the key to this code which will be kept in safe custody. If you agree 
to be a participant in this study, you will be screened as per the study protocol.  
 
 If you wish to find out more about this study before taking part, you can ask me all the questions you want or 
contact Dr.R.Radhakrishnan Studying M.D(S) scholar cum principal investigator of this study, attached to the 
National Institute of Siddha, Chennai (Mobile phone no:9444182233). You can also contact the 
Chairman/Member-secretary of Ethics committee, National Institute of Siddha, Chennai – 600047, Tel no: 
91-44-22411611, for rights and participation in the study. 
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   FORM IV C CERTIFICATE OF CONSENT 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to  ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
 
            I   consent voluntarily to participate as a participant in this study and 
understand that I have the   right to withdraw from the study at any time without in 
any way it affecting my further medical  care”. 
 
"I have received a copy of the information sheet/consent form". 
Date:  
 
Signature of the participant 
 
 
In case of illiterate participant, 
 
             “I have witnessed the accurate reading of the consent form to the potential 
participant, and the  individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
 
 
 
Date: 
 
 
 Signature of a witness  
       Left thumb Impression of the  Participant  
  
 
 (Selected by the participant bearing no connection with the survey team) 
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PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
      FORM IV D DIETARY ADVICE FORM 
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PRE CLINICAL AND CLINICAL STUDY ON “AZHAL KEEL VAAYU ” (OSTEO ARTHRITIS) AND 
THE DRUG OF CHOICE IS “SARVA NOI LINGA CHENDURAM” (INTERNAL) AND MAASHA 
THYLUM( EXTERNAL) 
                                                    FORM –IV-F 
                               ADVERSE DRUG  REACTION FORM 
 
Reg No:32101203/2012-13 
Serial No:      OP/IP No: 
Name:       Age:                                          Gender:  M/F 
 
Date of trial commencement: 
Date of the adverse reaction occur; 
Description of Adverse reaction: 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
Signature of the Lecturer:                                                             
 
         Signature of the HOD 
ASSESSMENT FORM 
 
FORM I SCREENING AND  SELECTION PROFORMA 
FORM I A HISTORY PROFORMA ON ENROLLMENT 
FORM ll CLINICAL ASSESSMENT ON ENROLLMENT 
FORM ll A CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
FORM lll LABORATORY INVESTIGATION ON ENROLLMENT AND  
    CONCLUSION OF TRIAL 
FORM IV  ADRUG COMPLIANCE FORM  
FORM IV B INFORMATION SHEET  
FORM IV C CONSENT FORM 
FORM IV D DIETARY ADVICE FORM 
FORM IV E WITHDRAWAL FORM 
FORM IV F ADVERSE REACTION FORM 
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